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ABSTRACT 
EFFICACY OF DEFERASIROX IN PREVENTING COMPLICATIONS OF IRON 
OVERLOAD IN THE IRON OVERLOADED GERBIL 
 
By Rabaa M. Al-Rousan 
 
Iron overload is a significant, world-wide problem that results in several 
chronic diseases including cardiovascular, hepatic and pancreatic complications. 
The newly developed, orally effective, iron chelating agent deferasirox is thought 
to offer tremendous promise as an alternative to deferoxamine. However, the 
efficacy and safety profile of deferasirox is not yet clear. In the present study, the 
efficacy of deferasirox in removing iron from target tissues has been examined 
using the gerbil model of iron overload.  
Deferasirox administration resulted in a significant reduction of iron from 
cardiac and hepatic tissue. In addition deferasirox reduced iron induced increase 
in cardiac and hepatic oxidative stress indices including ferritin expression, 
superoxide production, protein oxidation, and ERK1/2, P38, and JNK 
phosphorylation. These results indicate that deferasirox is capable of attenuating 
iron- induced oxidative stress. Continuing our investigation we observed that iron 
overload was also associated with an increase in hepatic cell death and 
upregulation of Bax/Bcl-22, Bad expression, and caspase-3 cleavage. These 
levels were significantly lower with deferasirox treatment suggesting a protective 
role against cell death. 
The primary overall goal of managing iron overload is to reduce/prevent 
cardiac or other organ complications. In the present study we examined the 
effect of iron overload on cardiac remodeling and functional parameters, and the 
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effectiveness of chronic deferasirox administration to prevent or reduce these 
changes using electro- and echocardiographic procedures. Compared to control, 
iron overload was associated with left ventricular remodeling, arrhythmia, valve 
regurgitation, and a decline in cardiac function.  These changes were highly 
preserved with deferasirox treatment. 
Following the preceding studies, we demonstrated a reduction in tissue 
iron with deferasirox treatment in the iron overloaded gerbil model. The findings 
of the present report established for the first time that deferasirox treatment is 
capable of attenuating iron-induced increase in oxidative stress indices, tissue 
ferritin protein expression, cell death, and more importantly, iron related 
cardiovascular alterations. These findings suggest that deferasirox may be useful 
in protection against iron-induced organ damage. The present report also 
provides data elaborating on the possible mechanism by which iron overload 
contributes to cellular injury, thereby allowing the development of better 
therapeutic regimens to control this disorder.   
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CHAPTER I 
INTRODUCTION 
 
Iron represents a paradox for living systems as it is essential for a wide variety of 
metabolic processes, but also toxic if in excess. Iron is an indispensable constituent of 
living cells and organisms due to its involvement in fundamental functions, which, 
among others, include oxygen transport, transfer of electrons in the respiratory chain 
and DNA synthesis (Ponka  1999).  The chemical basis underlying the versatility of iron 
for use in such crucial functions is provided by its unique ability to serve as both an 
electron donor and acceptor, thus representing a potential partner in redox reactions. 
However, this fundamental chemical property also is the basis of its toxicity, which 
poses a threat when iron is present in excess or  in non-protected forms (Eaton and 
Qian 2002). Thus, organisms were compelled to solve one of the many paradoxes of 
life, that is, to keep "free iron" at the lowest possible level through the evolution of 
specialized molecules for the acquisition, transport, and storage of iron in a soluble, 
nontoxic form to meet cellular and organismal iron requirements. Moreover, organisms 
are equipped with highly sophisticated mechanisms that coordinately regulate cellular 
iron uptake and storage and maintain iron in the intracellular labile pool at appropriate 
levels (MacKenzie, Iwasaki et al. 2008). 
Under conditions of iron overload this tight regulatory mechanism is disrupted 
resulting in the accumulation of iron in toxic levels (Hershko, Link et al. 1998). Iron 
overload can result from both primary and secondary causes. Primary iron overload 
(hereditary hemochromatosis) results from genetic disorders of iron metabolism that 
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cause excessive absorption of iron from the diet or deficient iron transport within the 
body. Secondary iron overload results from factors that bypass normal iron metabolic 
pathways, such as multiple blood transfusions (transfusional iron overload), or acute or 
chronic iron poisoning (Kushner, Porter et al. 2001). As transfusion therapy for chronic 
anemias and medical care has become more widely used, iron overload has become 
increasingly more common (Wood, Skoien et al. 2009). Indeed, it is estimated that in 
excess of two million individuals in the United States and up to one hundred million 
humans worldwide acquire some degree of iron overload and tissue accumulation of the 
metal (Hahalis, Alexopoulos et al. 2005). 
Iron toxicity occurs when the amount of circulating iron exceeds the amount of 
transferrin available to bind it forming non-transferrin bound iron (NTBI) (Andrews 
2005). NTBI enters the cell at a high rate through a transferrin receptor-independent 
pathway leading to iron accumulation in metabolically active tissues such as the liver, 
heart, and pancreas (Hershko 2007). If left undiagnosed or untreated, excess iron in the 
body is likely to cause cumulative toxicity which can lead to heart failure, hepatic 
cirrhosis, and diabetes mellitus (Kohgo, Ikuta et al. 2008).   
The mechanism(s) for iron mediated cellular injury are not clear, However, the 
formation of the highly toxic hydroxyl radical via the Fenton reaction has been 
suggested to be involved. Hydroxyl radical and other iron-mediated reactive oxygen 
species (ROS) induce protein oxidation, lipid peroxidation, and DNA damage resulting 
in loss of normal cellular functions (Galaris and Pantopoulos 2008). Iron is also 
inhibitory to the proper functioning of ion channels including L-type calcium channels, 
ryanodine sensitive calcium channels, fast-sodium channels, as well as the rectifier 
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potassium channels, which can lead to the development of arrhythmias and poor 
cardiac function in iron overload conditions (Wood, Enriquez et al. 2005). 
As the human body has no inherent mechanism to remove excess iron, iron 
chelating agents are used to treat iron overload. The goal of iron chelation therapy is to 
remove the amount of iron accumulated and, as required, to reduce the existing iron 
burden (Hershko, Link et al. 2005; Cianciulli 2008). To date, only deferoxamine is 
globally available for the first-line treatment of transfusion-related iron overload. While 
deferoxamine is effective, its administration is burdensome as it requires overnight 
subcutaneous infusions for 5-7 nights/week. As such, many patients do not undergo 
iron chelation therapy, exposing themselves to the dangers of iron overload (Chaston 
and Richardson 2003). Deferiprone has been used for approximately 20 years and is 
approved in Canada and Europe as a second-line therapy for patients unable to receive 
deferoxamine or for those in which deferoxamine is less effective (Victor Hoffbrand 
2005).  Although administered orally, the short half live of deferiprone necessitates 
multiple daily oral doses for effectiveness.  Like deferoxamine, deferiprone therapy is 
also problematic as it is associated with serious toxic side effects including 
transaminase increase, joint problems, severe neutropenia, and rare but life threatening 
agranulocytosis (Kontoghiorghes, Neocleous et al. 2003). Further, because three 
molecules of deferiprone are required to bind one molecule of iron, the ability of 
deferiprone to adequately control body iron burden for long periods of time (4-6 years) is 
questionable.  Studies have demonstrated that liver iron levels are not as well controlled 
with deferiprone as with deferoxamine, with liver iron levels remaining at levels above 
the threshold associated with systemic complications (Kontoghiorghes, Neocleous et al. 
2003).   
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Despite dramatic gains in life expectancy with deferoxamine chelation therapy, 
the leading cause of death for iron overload patients remains cardiac disease from 
cardiac iron deposition (Neufeld 2006). Strategies to reduce cardiac disease by 
improving chelation regimens have been of the highest priority. These strategies have 
included development of novel oral iron chelators to improve compliance, improved 
assessment of cardiac iron status, and careful epidemiologic assessment of outcomes 
with the current chelation regimens (Hider and Zhou 2005; Taher, Hershko et al. 2009). 
As a result of these efforts, the novel oral chelator deferasirox was recently approved by 
the Food and Drug Administration (FDA) for treatment of chronic iron overload in 
transfusion dependent patients and is the first oral medication approved in the United 
States for this purpose (Lindsey and Olin 2007; Stumpf 2007).  
Unlike deferoxamine, deferasirox is a long acting, orally effective iron chelating 
agent with favorable patient satisfaction  (Neufeld 2006; Cappellini and Pattoneri 2009). 
Deferasirox is a novel rationally designed iron chelator that has been selected from 
more than 700 compounds (Cappellini and Piga 2008). It represents a new class of 
tridentate iron chelators with a high specificity for iron (Cario, Janka-Schaub et al. 
2007).  Deferasirox possesses oral activity with around 70% bioavailability and long 
plasma half life (8 to 16 hours) allowing once daily dosing.  Deferasirox is well tolerated 
as it is associated with relatively few side effects and a favorable pharmacokinetic 
profile (Stumpf 2007). As such, deferasirox is expected to greatly enhance the 
acceptance of iron chelation therapy, especially for children, and offers a new 
alternative to the burdensome continuous infusion therapy. However, due to the limited 
information regarding its effectiveness in removing tissue iron, deferasirox is less 
frequently prescribed and is only available through specialty pharmacies where patients 
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have limited access to the medication. Deferoxamine has been the mainstay of iron 
chelation therapy and still remains the most commonly used for the control of iron 
overload conditions (Vichinsky, Pakbaz et al. 2008). It is clear that there is a critical lack 
of information regarding several aspects of deferasirox therapy including whether or not 
deferasirox is protective against iron-induced cardiac complications. This latter point is 
important as this information is crucial to establishing the efficacy and safety profile of 
deferasirox for fully justified use in human iron-overload therapy. 
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PURPOSE 
 
To date, only one investigation has examined the efficacy of deferasirox in 
removing tissue iron in the gerbil model (Wood, Otto-Duessel et al. 2006). The effect of 
deferasirox treatment on cellular indices of oxidative stress and iron-related cardiac 
complications is not known. To address these gaps in our understanding, the purpose of 
this research project was to examine: i) whether deferasirox is effective in removing iron 
from target tissues and whether iron removal, if present, is associated with the reduction 
of iron overload-related cell injury, and ii) whether deferasirox treatment can reduce or 
prevent cardiovascular complications associated with iron overload. It is anticipated that 
the outcomes derived from this study will be invaluable for understanding the efficacy 
profile of deferasirox and will contribute important insight into the nature of the 
protective mechanism(s) involved. 
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SPECIFIC AIMS 
 
Iron overload is an increasing worldwide problem associated with serious 
complications. The present standard of care for iron overload is iron chelation by 
deferoxamine; however, the use of this treatment is burdensome, invasive and thus 
associated with low patient adherence (Brittenham 2003). The new iron chelating agent 
deferasirox is thought to offer tremendous promise as an alternative to deferoxamine 
(Olivieri and Brittenham 1997; Franchini 2005; Cappellini and Taher 2008).  A review of 
the scientific literature, however, demonstrates that the efficacy and safety profile of 
deferasirox is not yet clear (Porter, Taher et al. 2008; Vichinsky 2008).  Specifically, 
information regarding the ability of deferasirox to protect against iron induced 
cardiovascular alterations is lacking. This is important as it limits the utilization of a 
potentially useful medication. The long-term goals are to improve our understanding of 
deferasirox efficacy and safety in an endeavor to help improve the quality of life of 
patients with iron overload. This study aims to firstly, determine whether deferasirox is 
capable of removing iron from target tissues and reduce oxidative stress associated 
with iron overload and secondly, to determine whether deferasirox is protective against 
iron overload-induced cardiovascular alterations. These goals will be accomplished by 
the following specific aims. 
 
SPECIFIC AIM I: To determine if deferasirox is able to reduce cardiac iron 
content, iron-induced ferritin upregulation, and iron-related increases  in indices 
of oxidative stress such as superoxide overproduction, protein oxidation, and the 
phosphorylation of the mitogen activated protein kinase (MAPK) proteins 
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extracellular signal regulated kinase 1/2 (ERK1/2)-, p38-, and c-Jun N-terminal 
kinase (JNK).  
 
SPECIFIC AIM II: To determine if deferasirox is able to reduce hepatic iron 
content, iron-induced ferritin upregulation, and iron related increases in indices of 
oxidative stress and the effect of these changes, if present, on  the incidence of  
iron-related changes in cell death and apoptotic signaling. 
 
SPECIFIC AIM III: To determine the long term cardiovascular complications 
associated with iron overload and to determine if chronic deferasirox 
administration is able to prevent/reduce these complications including those 
related to cardiac remodeling and functional abnormalities. 
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
 
 The following chapter presents a review of the pertinent literature concerning the 
present study.  Specifically, the following areas will be addressed:  Body iron 
homeostasis, disorders of iron overload, mechanisms of iron mediated toxicity, methods 
of detecting body iron, management of iron overload, and animal models of iron 
overload. 
 
2.1 BODY IRON HOMEOSTASIS 
 2.1.1 Normal distribution of body iron stores 
The total amount of iron in the human body is approximately 3-4 g (Andrews 
2005). The vast majority of body iron (about 2.5 g) is contained in hemoglobin. A 
significant portion of iron (~ 400 mg) is devoted to cellular proteins that use iron for 
important cellular processes like storing oxygen (myoglobin), or performing energy-
producing redox reactions (cytochromes). Approximately 3-4 mg circulates in the 
plasma as an exchangeable pool bound to transferrin. This chelation serves three 
purposes: it renders iron soluble under physiologic conditions, it prevents iron-mediated 
free radical toxicity, and it facilitates transport into cells (MacKenzie, Iwasaki et al. 
2008). The sum of all iron binding sites on transferrin constitutes the total iron binding 
capacity (TIBC) of plasma. Under normal circumstances, about one-third of transferrin 
iron-binding pockets are filled and non-transferrin-bound iron in the circulation is virtually 
nonexistent. 
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Physiologically, most stored iron (~1g) is bound by ferritin molecules; the largest 
amount of ferritin-bound iron is found in hepatocytes, bone marrow, and spleen (Lash 
and Saleem 1995). Of these, the liver is considered the primary physiologic source of 
reserve iron in the body. Reticuloendothelial cells store iron as part of the process of 
phagocytosis and breakdown of aging red cells. These cells extract iron from heme and 
return it to the circulation bound to transferrin (Andrews and Schmidt 2007). There is no 
specific physiological mechanism for iron excretion from the body and thus the amount 
of body iron is controlled by the rate of its absorption by duodenal enterocytes. On a 
daily basis, adult humans absorb 1–2 mg of iron from the diet to compensate for non-
specific iron losses such as that which occurs following desquamation or blood loss 
(Donovan, Roy et al. 2006). 
2.1.2 Regulation of iron absorption 
It is thought that the first step of iron absorption involves the reduction of Ferric 
iron Fe(III) in the intestinal lumen by ferroreductase Dcytb (duodenal cytochrome b), to 
the more soluble form Fe(II) (Pantopoulos 2004). Ferrous iron Fe(II) is then transported 
across the basolateral membranes of the enterocytes by divalent metal transporter 1 
(DMT1) (Figure 1, Panel A). The export of Fe(II) across the basolateral membranes of 
enterocytes to circulation is mediated by ferroportin. This step is coupled with 
reoxidation of ferrous to ferric iron by membrane-bound hephastin (or its plasma-soluble 
homologue ceruloplasmin) (Donovan and Andrews 2004; Pantopoulos 2004). Plasma 
iron is immediately scavenged by the plasma iron carrier transferrin (Tf) in 2:1 ratio. 
Plasma Tf binds to its cell surface receptor (TfR) and the complex is internalized by 
endocytosis. Acidification of the endosomes results in the release of ferric iron from Tf 
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and reduction and subsequent transport of ferrous iron across the endosomal 
membranes by DMT1. The pathway is completed by recycling of the apo Tf-TfR 
complex to the cell surface and release of apoTf which is transported back to the 
circulation to carry new iron ions (Figure 1, Panel B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (A) Schematic representation of iron transport across duodenal 
epithelial cells. (B) Cellular iron uptake from transferrin (Tf) via receptor 
mediated endocytosis. (Pantopoulos 2004) 
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Following its release from transferrin within endosomes, iron is thought to enter 
the labile iron pool (LIP) where it becomes available for intracellular use or for storage in 
ferritin  (Andrews 2008). Another source of iron for this pool comes from the breakdown 
of nonheme-  and heme- iron-containing proteins. It has been proposed that iron in this 
pool may form complexes with citrate, sugars, various amino acids, pyridoxal, or 
nucleotides, but the details regarding the regulation of this pool remain elusive (Kakhlon 
and Cabantchik 2002). 
2.1.3 Regulation of systemic iron homeostasis 
Iron homeostasis in mammals is regulated at the level of intestinal absorption, as 
there is no excretory pathway for iron. Hepcidin, a circulating peptide hormone, is the 
master regulator of systemic iron homeostasis, coordinating the use and storage of iron 
with iron acquisition (Hershko 2006). This hormone is primarily produced by 
hepatocytes and is a negative regulator of iron entry into plasma (Sela 2008). Hepcidin 
acts by binding to ferroportin, an iron transporter present on cells of the intestinal 
duodenum, macrophages, and cells of the placenta (Ramey, Deschemin et al. 2009). 
Binding of hepcidin induces ferroportin internalization and degradation resulting in 
reduced iron entry into plasma. Conversely, decreased expression of hepcidin leads to 
increased cell surface ferroportin and increased iron absorption. Plasma hepcidin levels 
are regulated by different stimuli, including cytokines, plasma iron, anemia, and hypoxia 
(Ganz 2003; De Domenico, Ward et al. 2007). Overexpression of hepcidin has been 
linked to the development of anemia, while low hepcidin is associated with hereditary 
hemochromatosis (De Domenico, Ward et al. 2007). 
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2.1.4 The IRP-IRE regulation of cellular iron homeostasis 
The iron-responsive element, (IRE), is present in the mRNA of various iron 
regulatory proteins including ferritin and the transferrin receptor. Enlargement of the 
intracellular transit iron pool, in general, leads to a stimulation of ferritin synthesis and 
decrease in the expression of transferrin receptors (Pantopoulos 2004).  
Iron-dependent regulation of both ferritin and transferrin receptors is mediated by 
virtually identical IREs. The IREs are hairpin structures recognized by iron-regulatory 
protein-1 (IRP1). When cellular iron becomes limiting, the IRP-1 becomes bound to the 
IRE located within the 5' UTR of the ferritin mRNA and this represses the translation of 
ferritin (Figure 2, upper panel). A similar mechanism regulates the expression of 
transferrin receptor. Under conditions of low iron, IREs within the 3' UTR of the 
transferrin receptor mRNA become bound by IRP-1, which in turn stabilizes the 
transcript against ribonuclease activity (Figure 2, lower panel). Together, these 
responses lead to increased iron uptake and reduced iron storage. Conversely, the 
expansion of the labile iron pool inactivates IRP-1, resulting in an efficient translation of 
ferritin mRNA and rapid degradation of transferrin receptor mRNA. These responses 
lead to decreased iron uptake and elevated iron storage (Ponka 1999; Munoz, Villar et 
al. 2009). 
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Figure 2. Role of cellular iron level in the regulation of ferritin and transferrin 
receptor expression via the IRE/IRP system. (Ponka  1999) 
 
 
2.2 DISORDERS OF IRON OVERLOAD 
Iron overload is a group of disorders caused by the accumulation of iron in the 
body. These disorders can be either acute or chronic in nature (Heeney and Andrews 
2004).  Acute iron overload is typically caused by excess iron intake such as that seen 
after the accidental ingestion of large quantities of iron-containing multivitamins, or iron 
supplements in young children. Acute iron overload has been found to irritate the 
stomach lining, and is associated with nausea and vomiting. If the intake is excessive, 
damage to internal organs (e.g. brain and the liver), metabolic acidosis and death 
oftentimes result  (Singhi, Baranwal et al. 2003). In contrast to that observed for acute 
iron overload, the manifestation of chronic iron overload appears to be more varied as 
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this disorder can be caused by primary (genetically determined) conditions or arise 
secondary to other conditions (Piperno 1998). 
2.2.1 Primary iron overload (Hereditary hemochromatosis) 
Hereditary hemochromatosis is caused by mutation of genes involved in 
regulation of iron homeostasis (Table 1). The majority depend on defined- HFE gene 
mutations discovered in 1996 and are referred to as “classical hemochromatosis”  
(Janssen and Swinkels 2009).  
 
Table 1. Hereditary hemochromatosis; Classification and associated gene products 
Classification Associated gene product 
 Type I:  "classical" hemochromatosis HFE 
Type IIA: Juvenile hemochromatosis Hemojuvelin “HJV” 
Type IIB: Juvenile hemochromatosis Hepcidin antimicrobial peptide “HAMP” 
Type III Transferrin receptor-2 “TFR-2” 
Type IV: African iron overload Ferroportin 
Neonatal hemochromatosis Unknown 
Aceruloplasminemia Ceruloplasmin 
Congenital atransferrinemia Transferrin 
GRACILE syndrome BCS1L 
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Other gene mutations have been discovered later and are grouped together as 
"non-classical hereditary hemochromatosis" or "non-HFE hemochromatosis". Most 
types of hereditary hemochromatosis have autosomal recessive inheritance, while type 
IV has autosomal dominant inheritance (Janssen and Swinkels 2009). 
While the genetic mutations causing several variants of hemochromatosis have 
been identified, the exact function of these genes is yet unknown. However, most 
genetic forms of iron overload seem to be associated with hepcidin deficiency resulting 
in increased intestinal absorption of iron (Lee and Beutler 2009). An exception is type IV 
hemochromatosis where ferroportin becomes mutated resulting in a deficiency in the 
action of hepcidin (Fernandes, Preza et al. 2009). 
2.2.2 Secondary iron overload 
Secondary iron overload may result from chronic blood transfusion, from 
increased gastrointestinal absorption of iron, or from some combination thereof 
(Kushner, Porter et al. 2001). 
Chronic blood transfusion: An adequate transfusion program can sustain life in 
patients with severe chronic refractory anemia, but transfusion therapy alone produces 
a progressive accumulation of the iron contained in transfused red cells. In patients with 
severe congenital anemias, such as thalassemia major and the Blackfan-Diamond 
syndrome, regular transfusions can prevent death from anemia in infancy and permit 
normal growth and development during childhood but, if left uncontrolled, may result in 
severe iron overload by adolescence (Borgna-Pignatti, Rugolotto et al. 2004; Chen, 
Tseng et al. 2009). Treatment of acquired transfusion-dependent anemias, such as 
aplastic anemia, pure red cell aplasia, and hypoplastic or myelodysplastic disorders, 
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among others, may also result in the development of marked iron overload (Malcovati 
2009). In addition, although sickling disorders (e.g., sickle cell anemia) are not 
transfusion-dependent, these patients may acquire a considerable iron load from 
repeated transfusions for the prevention of stroke, painful crises, and other recurrent 
complications (Ballas 2001).  
About 200 to 250 mg of iron is added to the body iron load with each unit of 
transfused red cells. Most transfusion-dependent patients require 200 to 300 ml/kg of 
blood a year; for example, a 70 kg adult requires about two to three units of blood every 
3 to 4 weeks, adding about 6 to 10 g of iron a year (Agarwal 2009). The severity of iron 
toxicity seems to be related to the magnitude of the body iron burden. Almost all 
patients who have been treated with transfusion alone and have received 100 or more 
units of blood (about 20 to 25 g of iron) develop cardiac iron deposits, often in 
association with signs of hepatic, pancreatic, and endocrine damage (Brittenham 2006) 
Ineffective erythropoiesis: This disorder occurs in patients with congenital 
dyserythropoietic anemia, pyruvate kinase deficiency, thalassemia major, thalassemia 
intermedia, sideroblastic anemia, some myelodysplastic anemias, and other anemic 
disorders in which the incorporation of iron into hemoglobin is impaired (Sarnaik 2005; 
Rivella 2009). As a result of ineffective erythropoiesis, plasma iron turnover increases 
drastically, resulting in excessive production of growth differentiation factor 15 (GDF15) 
(Tanno, Bhanu et al. 2007). GDF15 is a member of the transforming growth factor-β 
(TGF-β) superfamily which, at high levels, is able to suppress hepcidin production, 
resulting in increased intestinal iron absorption and release of catabolic iron from 
macrophages (Gardenghi, Marongiu et al. 2007). 
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Chronic liver disease: Some patients with chronic liver disease, for example 
alcoholic cirrhosis, may experience minor or modest degrees of iron loading as a result 
of increased dietary iron absorption (Schulz and Sanft 1984; Duane, Raja et al. 1992). 
The mechanisms responsible for the increased gastrointestinal iron uptake have not 
been identified, although ineffective erythropoiesis and hyperferremia associated with 
alcohol-induced folate and sideroblastic abnormalities have been proposed as etiologic 
factors (Gentry-Nielsen, Preheim et al. 2001; Harrison-Findik 2007). Body iron stores 
are increased only to a minor degree, but in alcoholic cirrhosis, the higher the liver iron 
the shorter the survival. 
Focal sequestration of iron:  Focal iron sequestration is found in rare disorders, 
including idiopathic pulmonary hemosiderosis and renal hemosiderosis (Piperno 1998). 
Such abnormal iron deposition is also associated with neurologic abnormalities 
including Friedreich ataxia, in which decreased iron-sulphur-cluster and heme formation 
leads to mitochondrial iron accumulation primarily in sensory neurons, myocardium and 
endocrine glands (Boddaert, Le Quan Sang et al. 2007; Gucev, Tasic et al. 2009). 
 
2.3 CLINICAL MANIFESTATION OF IRON OVERLOAD 
Because humans lack a physiologic means of eliminating excess iron, iron 
progressively accumulates and eventually damages the liver, heart, pancreas, and other 
organs with death usually occurring as a result of cardiac failure (Hershko 2007). In 
younger patients, the iron burden results in growth failure and, in adolescence, delayed 
or absent sexual maturation (Nabavizadeh, Anushiravani et al. 2007; Safarinejad 2008). 
The precise manifestations of iron overload, however, depend on different factors 
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including, the underlying abnormality, body iron burden, the rate at which the increase in 
body iron has occurred and the distribution of the excess iron between storage sites 
(Kontoghiorghes, Pattichi et al. 2000; Wood, Skoien et al. 2009). 
Initially, the deleterious effects of iron loading are not clinically significant, and 
manifest as discomfort in hand joints, increased skin pigmentation and fatigue 
(MacKenzie, Iwasaki et al. 2008). As tissue iron accumulates, liver damage ranging 
from fibrosis to cirrhosis can develop in affected individuals. In hereditary 
hemochromatosis, hepatomas develop almost exclusively in patients with hepatic 
cirrhosis and are the ultimate cause of death in 20% to 30% of these patients 
(MacKenzie, Iwasaki et al. 2008).  
Iron overload also leads to iron deposition in the heart and endocrine tissues. 
Chronically elevated cardiac iron concentrations impair diastolic function, increase the 
propensity for arrhythmias, and, ultimately, cause end stage cardiomyopathy (Wood, 
Enriquez et al. 2005). Iron overload cardiomyopathy, defined as the presence of systolic 
or diastolic cardiac dysfunction secondary to increased iron deposition, is an important 
cause of heart failure and is the primary determinant of survival in patients with iron 
overload (Wood, Enriquez et al. 2005; Lekawanvijit and Chattipakorn 2009). 
Cardiomyopathy develops initially as a severe diastolic dysfunction; in the later stages 
however, heart failure progresses to severe systolic dysfunction and ventricular dilation. 
Death ensues promptly in the later stages due to cardiac failure and/or severe 
arrhythmias (Bartfay 1999). Other targets of iron deposition include pancreas (glucose 
intolerance, diabetes), posterior pituitary gland (secondary hypogonadism), joints 
(arthropathy), and neurons (neurological abnormalities) (Gamberini, De Sanctis et al. 
2008) . 
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2.4 MECHANISMS OF IRON MEDIATED TOXICITY 
2.4.1 Formation of non-transferrin bound iron 
Iron toxicity results when iron in the circulation exceeds serum transferrin iron-
binding capacity, leading to the appearance of non-transferrin-bound iron (NTBI) (Eaton 
and Qian 2002). The exact nature of NTBI is not clear, but it is believed to consist of 
labile low-molecular weight complexes of iron with plasma components such as 
albumin, citrate and phosphate (Cabantchik, Breuer et al. 2005). Unlike transferrin–
bound iron, NTBI enters cells via a transferrin receptor-independent mechanism and at 
a rate exceeding the normal uptake of transferrin iron. NTBI uptake into cells bypasses 
the normal negative feedback regulatory mechanisms that control cellular iron uptake 
and metabolism. Once NTBI enters the cells, it is rapidly buffered by ferritin, limiting its 
potential for redox damage or other harmful interactions in the cell (Wood, Enriquez et 
al. 2005). Nonetheless, all buffering systems have limited capacity or can be disrupted 
by other factors. Thus, excess uptake of NTBI, combined with the lack of an effective 
iron excretory pathway, leads to the expansion of the labile intracellular iron pool (LIP), 
resulting in the formation of highly-reactive oxygen free radicals (Kruszewski 2003; 
Ozment and Turi 2009). 
Ferritin molecules aggregate over time to form clusters, which are engulfed by 
lysosomes and degraded (Iancu et al. 1977, Bridges 1987). The end-product of this 
process, hemosiderin, is an amorphous agglomerate of denatured protein and lipid 
interspersed with iron oxide molecules (Wixom et al. 1980). Although the iron enmeshed 
in this insoluble compound constitutes an endstage product of cellular iron storage, it 
remains in equilibrium with soluble ferritin. Ferritin iron, in turn, is in equilibrium with iron 
complexed to low molecular weight carrier molecules (Konijn, Glickstein et al. 1999). 
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Therefore the introduction into the cell of an effective chelator captures iron from the low 
molecular weight "toxic iron" pool, draws iron out of ferritin, and eventually depletes iron 
from hemosiderin as well, though only very slowly (Crichton and Ward 2003).  
2.4.2 Chemistry of iron and ROSs 
The initial reactive oxygen intermediate produced in most cases of oxidative 
stress is superoxide (O2·−) (Turrens 2003). Cellular sources of O2·− include 
mitochondria and lysosomes, with the production of this molecule exacerbated under 
conditions of hypoxia or ischemia. Once formed, superoxide is rapidly converted to 
H2O2 by the action of superoxide dismutases (SOD):  
 
2O2·− + 2H+ → H2O2 + O2 
 
Neither O2·− nor H2O2 are strong oxidizing agents, however when free iron ions are 
available, Fenton-type reaction takes place (Galaris and Pantopoulos 2008), producing 
the extremely reactive hydroxyl radical (·HO): 
 
Fe2+ + H2O2 → Fe3+ + OH- + OH• 
 
Superoxide anion may reduce Fe3+ back to Fe2+ (Haber-Weiss reaction), thus allowing 
iron to act as an autocatalyst of the reaction (Kell 2009): 
 
Fe3+ + O2·− → Fe2+ + O2 
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In addition, Fe2+ and certain Fe2+ chelates react with lipid hydroperoxides (LOOH), as 
they do with hydrogen peroxide, splitting the O–O bond. This gives rise to the alkoxyl 
radical (LO·), which can also abstract H· from polyunsaturated fatty acids and from 
hydroperoxides (Kell 2009): 
 
LOOH + Fe2+ → OH- + LO• + Fe3+ 
 
Alternatively, Fe3+ can initiate the reaction with lipid hydroperoxides (LOOH). The 
resulting peroxyl radicals (LOO·) can continue propagation of lipid peroxidation:  
 
LOOH + Fe3+ → H+ + LOO• + Fe2+ 
 
Furthermore, elevated superoxide liberates free iron from ferritin, thereby 
providing a positive feedback loop where the increase in the amount of free iron 
catalyses the production of further hydroxyl radical formation  (Keyer and Imlay 1996) 
(figure 3).  
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2.4.3 Targets of iron-driven cellular damage 
Given the tendency of transition metals such as iron to amplify oxidant damage, 
the fact that organs with very active mitochondria are targeted in iron overload disorders 
is probably no coincidence (Eaton and Qian 2002). The liver and heart have high 
steady-state production of O2·−  and H2O2, largely derived from mitochondrial activity 
(Han, Williams et al. 2001). The pancreatic beta cell is also rich in mitochondria and is 
highly sensitive to oxidant-generating substances (Maiese, Chong et al. 2007). 
However, although the hepatic, cardiac, and pancreatic beta cell pathologies caused by 
iron overload probably involve an iron-driven oxidative component, the precise 
mechanisms through which reactive iron conspires with oxygen to amplify cellular 
oxidant damage remain unknown. The fundament of iron-mediated oxidant damage 
may be the tendency of free iron to associate with oxidizable targets within cells (e.g., 
Figure 3. Catalysis and autocatalysis in the Haber-Weiss and 
Fenton reactions leading to the production of the hydroxyl 
radical, including the liberation by superoxide of free iron from 
ferritin. (Kell, 2009) 
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polyunsaturated fatty acids, proteins, or DNA) and to engage in site-specific oxidation 
reactions  (Lucesoli and Fraga 1995). These latter reactions have often been ascribed 
to the hydroxyl radical but more likely represent multiple reactions arising from 
complexes of iron bound to particular target molecules and oxidants which, upon 
reaction with the iron, form a highly oxidizing intermediate (ferryl or perferryl) (Eaton and 
Qian 2002). 
Iron catalyzes the production of free radicals which can directly interact with 
many biological macro- and small molecules, leading to oxidative membrane damage 
throughout the cell (Galaris and Pantopoulos 2008). Excessive free radical generation 
leads to increased lipid peroxidation, protein oxidation, and gene modulation, triggering 
cellular damage and antioxidant depletion (Livrea, Tesoriere et al. 1996; Brown, Kinter 
et al. 1998; Bartfay, Dawood et al. 1999). Metal-catalyzed damage to proteins includes 
loss of histidine residues, bityrosine cross links, oxidative scission, the introduction of 
carbonyl groups (through, e.g., oxidative deamination), and the formation of protein-
centered alkyl, alkylperoxyl, and alkoxyl radicals (Valko, Rhodes et al. 2006). 
Polymerization and denaturation of proteins and proteolipids form insoluble structures 
typically known as lipofuscin (Kell 2009). Elevated cellular iron levels also leads to DNA 
damage. Products of reactions between DNA, iron, and oxidants are not yet fully 
elucidated but include strand breaks, oxidatively modified bases, and DNA protein 
cross-links (Meneghini 1997; Gao, Campian et al. 2009). The relative importance of all 
these products in long-term iron-mediated DNA damage is not yet known. Alterations in 
gene expression and gene modulation have also been reported (Barouki and Morel 
2001; Parkes and Templeton 2003); however, whether these changes represent 
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controlled interactions through iron response elements or nonspecific effects from redox 
damage is unclear. 
  Iron is preferentially taken up by mitochondria and lysosomes. In the 
mitochondria, iron accumulation results in peroxidation of polyunsaturated fatty acids 
(PUFA) within membrane phospholipids (Britton, O'Neill et al. 1990), disruption of 
mitochondrial respiratory enzymes (Bacon, O'Neill et al. 1993; Link, Saada et al. 1998) 
and mitochondrial DNA damage (Gao, Campian et al. 2009). Accumulation of iron within 
the cellular lysosomal compartment will sensitize the lysosomes to damage and rupture 
with release of damaging lysosomal digestive enzymes into the cytoplasm of the cell 
(Stal, Glaumann et al. 1990). Minimal release of lysosomal enzymes may induce 
transient reparative autophagocytosis, while moderate lysosomal rupture is followed by 
caspase activation and apoptosis (Kurz, Terman et al. 2008). Severe oxidative stress, 
resulting in massive lysosomal breakdown, is associated with necrosis (Kurz, Terman et 
al. 2008).  
Iron can also directly interact with ion channels. For example, ferrous iron has 
similar size and charge to that of calcium ions and can permeate through cardiac L-type 
calcium channels (LTCC) (Oudit, Sun et al. 2003). Fe2+ slows Ca2+ current inactivation 
resulting in increase in the time integral of the Ca2+ current and net Ca2+ influx, which 
may possibly contribute to the impaired diastolic function observed during the early 
stages of iron overload  (Oudit, Trivieri et al. 2006). With higher concentrations of 
ferrous iron there is a reduction in Ca2+ current due to competition with ferrous iron. This 
may contribute to the systolic dysfunction that is characteristic of more advanced iron-
overload cardiomyopathy (Oudit, Trivieri et al. 2006) . Ferrous iron can also directly 
interact with the ryanodine sensitive calcium channel in the sarcoplasmic reticulum 
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(Kim, Giri et al. 1995). This channel is responsible for activation of contraction and also 
modulates calcium reuptake in the sarcoplasmic reticulum.  
In addition to its effects on calcium homeostasis, intracellular iron impairs the 
function of membrane-bound fast-sodium channels as well as delayed rectifier 
potassium currents (Wood, Enriquez et al. 2005). The former channels are responsible 
for the rapid upstroke of the cardiac action potential. Channel blockage or other 
interference will slow cardiac conduction, and delay action potential spread across the 
myocardium (Wood, Enriquez et al. 2005). Hence it is not surprising that iron overload 
results in arrhythmias and poor cardiac function. 
 
2.4.4 ROS and iron-mediated intracellular signaling 
Mammalian cells exhibit a broad spectrum of responses toward oxidative stress, 
which is dependent on the severity of the stress encountered and the availability of 
catalytically active iron (Deb, Johnson et al. 2009). The members of mitogen-activated 
protein kinases (MAPKs), including ERK, JNK, and p38 subfamilies, have all been 
shown to be activated in response to oxidant injury and therefore could potentially 
contribute to influencing cell survival (Griendling, Sorescu et al. 2000). Each MAPK 
subtype is activated by phosphorylation on threonine and tyrosine residues by upstream 
dual-specificity kinases. In general, the ERK cascade appears to mediate signals 
promoting cell proliferation, differentiation or survival, whereas the p38 and JNK 
cascades appear to be involved in the cell responses to stresses (Martindale and 
Holbrook 2002). However, activation of distinct MAPK subtypes is dependent on the cell 
type and the stimuli. It was recently suggested that iron loading in vitro  induces p38 and 
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ERK 1/2 phosphorylation associated with an increase in ROS levels (Antosiewicz, 
Ziolkowski et al. 2007). 
Ferritin represents the main iron storage protein, and its concentration is mutually 
related with the cytosolic level of labile iron. Changes in iron availability regulate ferritin 
expression primarily at the translational level through specifically regulated protein-RNA 
interactions between IRPs and IREs as described earlier in this chapter. In iron overload 
conditions, serum ferritin expression is increased, which is used as one common 
diagnostic tool to reflect body iron status (Piperno 1998). 
Other pathways that are clearly linked to ROS include the induction of 
programmed cell death (apoptosis) (Orrenius 2007). Apoptosis is a genetically 
controlled response to eliminate unwanted cells that is involved in the regulation of cell 
number under several physiological and pathological conditions. High levels of ROS can 
lead to necrotic cell death, whereas low levels of ROS have been shown to induce 
apoptotic cell death (Denecker, Vercammen et al. 2001). Apoptosis is regulated through 
different mechanisms, including the expression of the members of the Bcl-2 protein 
family consisting of pro- and anti-apoptotic peptides interacting with each other by 
forming homo- and heterodimers. Bcl-2 is thought to act as negative regulator of 
apoptosis and has been thought to protect cells from ROS (Li, Ueta et al. 2004), 
although the mechanism by which this latter event occurs remains unclear. Conversely, 
Bax has been implicated to promote or accelerate cell death with recent data showing 
that Bax may be able to induce apoptosis by both caspase-dependent and -independent 
mechanisms. Recent studies have suggested that iron induces cell apoptosis via the 
promotion of Bax translocation, cytochrome c release, and caspase-3 activation (Yajun 
2005). Whether iron exerts its signaling effects independently or it simply participates in 
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reactions of ROS-mediated signaling is presently unknown and needs further 
investigation. 
 
2.5 METHODS OF DETECTING BODY IRON 
Both direct and indirect means for the assessment of body iron are available but 
no single indicator or combination of indicators is ideal for the evaluation of iron status in 
all clinical circumstances. As 90% of excess iron is deposited in the liver, measurement 
of hepatic iron stores provides the most quantitative means of assessing the body iron 
burden and may be considered the reference method for comparison with other 
techniques (Vermylen 2008). The invasive nature of the liver biopsy, however, means 
that other markers such as serum ferritin levels are frequently employed. Other 
approaches using biomagnetic susceptometry and magnetic resonance imaging (MRI) 
are also being assessed in order to identify an accurate, low-risk, and convenient 
approach to assessing patient iron status. 
 
2.5.1 Indirect Assessment  
Serum ferritin: Serum ferritin is easily measured using a commercially available 
kit. A ferritin level constantly below 2500 µg/L has been shown to reduce the risk of 
cardiac complications, but a target value of 1000 µg/L is recommended. Factors such as 
inflammation, ascorbate status, and hepatitis can affect serum ferritin levels (Olivieri, De 
Silva et al. 2000). Therefore, results should be interpreted with caution and a trend in 
the evolution of serial measurements is a better index than day-to-day variation. In 
patients with transfusion-dependent diseases, chelation should be initiated after 10–20 
blood transfusions or when ferritin level rises above 1000 µg/L (Vermylen 2008). 
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24–hour deferoxamine-induced urinary iron excretion: This includes 
measuring the amount of chelated iron in the urine after a single intramuscular dose or 
prolonged subcutaneous infusion of deferoxamine. The usefulness of this method has 
several limitations in the accurate assessment of body iron burden (Olivieri and 
Brittenham 1997). Most important is the poor correlation between urinary iron excretion 
and hepatic iron concentration which develops, at least in part, because the relative 
amounts of iron excreted into stool and urine vary with the dose of deferoxamine 
administered, body iron burden, and erythroid activity (Olivieri and Brittenham 1997). 
Chelator-induced urinary iron excretion is also vulnerable to extraneous influences by 
infection, inflammation, the activity and effectiveness of erythropoiesis, extramedullary 
hematopoiesis, liver disease, and ascorbic acid deficiency. 
 
Magnetic resonance imaging (MRI): MRI measures tissue iron concentration 
indirectly by detecting the paramagnetic influences of storage iron (ferritin and 
hemosiderin) on proton resonance behavior. Iron deposits act like little magnets when 
placed in a strong magnetic field, disrupting coherence among the emitted protons and 
darkening the image more quickly (Vermylen 2008). Liver iron content (LIC) determined 
using MRI shows excellent correlation with that obtained from liver biopsy 
(Papakonstantinou, Maris et al. 1995). Furthermore, MRI has the ability to evaluate the 
entire organ and gives more accurate measurement of LIC, particularly in patients with 
heterogeneous iron content (Li, Aisen et al. 2004). Although very promising, the 
widespread use of this method in many parts of the world may be hampered by the 
need for expensive equipment and trained personnel to perform the scan. 
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2.5.2 Direct assessment 
Liver biopsy: The measurement of liver iron content is the most accurate 
method for assessing body iron and thus it is referred to as the “gold standard” as there 
is a high correlation between LIC and total body iron (Alustiza, Castiella et al. 2007). 
The procedure also provides information about the severity of the liver disease. Liver 
biopsy, however, is an invasive technique that is associated with some pain and risk of 
hemorrhage and infection. Thus, it is not indicated for routine assessment. 
 
Superconducting quantum interference device (SQUID): SQUID provides a 
direct measure of tissue iron that is based on a fundamental physical property of ferritin 
and hemosiderin (Olivieri et al, 1997). SQUID is capable of measuring very small 
changes in magnetic flux. Iron stored as ferritin and hemosiderin is the only relevant 
paramagnetic material in the human body. The magnitude of paramagnetic response is 
directly related to the amount of iron in a certain volume of tissue (Vermylen 2008). This 
is a noninvasive method, with a linear correlation with LIC assessed by biopsy. 
However, equipment availability is extremely limited. 
 
2.6 MANAGEMENT OF IRON OVERLOAD 
Iron overload treatment is dependent on the underlying condition. Phlebotomy is 
currently the recommended iron overload treatment for most patients with hereditary 
excess iron, although iron chelation therapy could be an option for patients who cannot 
or choose not to undergo phlebotomy (Brissot 2009). For transfusional iron overload, 
iron chelation therapy is the first-line therapy (Cappellini 2005). 
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2.6.1 Phlebotomy 
The treatment of choice for hereditary hemochromatosis is phlebotomy to reduce 
the body iron levels to normal or near-normal and maintain them in that range (Tavill 
2001). In patients with hereditary hemochromatosis who develop cardiac failure, the use 
of both phlebotomy and chelation therapy has been suggested. Phlebotomy therapy 
should be started as soon as the diagnosis of the homozygous state for hereditary 
hemochromatosis has been established, as postponement is likely to increase the risk 
of organ damage from iron overload. The phlebotomy program should remove 500 ml of 
blood (containing 200 to 250 mg of iron) once weekly or, for heavily loaded patients, 
twice weekly until the patient is iron deficient (Brissot 2009).  
In patients with hereditary hemochromatosis, prolonged treatment is often 
needed. For example, if the initial body iron burden is 25 g, complete removal of the iron 
burden with weekly phlebotomy may require 2 years or more.  After the iron load has 
been completely removed, a lifelong program of maintenance phlebotomy is required to 
prevent reaccumulation of the iron burden (Tavill 2001). Typically, phlebotomy of 500 ml 
of blood every 3 to 4 months is needed. If phlebotomy therapy removes the iron load 
before diabetes mellitus or cirrhosis develops, the patient's life expectancy is expected 
to be normal. If cirrhosis develops, however, the risk of hepatocellular carcinoma is 
increased by more than 200-fold (Bacon 2001). Phlebotomy therapy is almost always 
indicated for patients with hereditary hemochromatosis, even when cirrhosis or organ 
damage is already present, as further progression of the disease can be stopped with 
the possibility of minimizing organ dysfunction (Brissot 2009). 
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2.6.2 Chelation therapy 
For patients requiring regular blood transfusions, iron chelation may represent 
life-saving therapy. In patients with thalassemia major, the availability of chelation 
therapy led to one of the most marked improvements in morbidity and mortality 
associated with a genetic disease (Cianciulli 2008; Agarwal 2009). The major goal of 
iron chelation therapy is to bind NTBI and intracellular labile iron, thereby effectively 
eliminating toxic iron (Porter 2007). Due to the cumulative nature of iron loading, 
continuous (24-hour) control of NTBI levels is desirable (Ozment and Turi 2009). 
Although the benefits of chelation therapy with regard to a reduction in morbidity 
and mortality may be apparent within a much shorter timeframe, it may take years for 
body iron levels to reach normal levels. The availability of effective iron chelation 
therapies has significantly extended the life expectancy of transfusion-dependent 
patients, and consistent therapy reduces the toxicity and organ damage associated with 
excess iron (Cario, Janka-Schaub et al. 2007). 
For any given patient, reaching their target body iron levels depends to a large 
extent on their ability to comply with long-term therapy, which itself is largely determined 
by the side effects, tolerability, perceived efficacy and convenience of the iron-chelating 
agent (Cohen 2006). Unfortunately, the survival and health benefits of current iron 
chelation agents decline measurably with even minimal reductions in compliance. 
Therefore, optimal compliance requires that patients both understand the nature of the 
threat of iron overload, and receive psychological and social support for continuing both 
blood transfusions and iron chelation therapy (Cohen 1990). 
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Three approved iron chelation agents are available currently: Deferoxamine, 
deferiprone, and deferasirox, with the approval and availability of these agents largely 
country specific (Cohen 2006). These three compounds are compared in table 2 to the 
properties of an ideal chelator. 
Deferoxamine (DFO)  
DFO, a hexadentate siderophore (Figure 4) isolated from Streptomyces pilosus, 
has been the clinical chelator of choice for the treatment of iron overload diseases since 
the 1970s (Brittenham 2003). The high affinity of this siderophore for Fe(III) renders iron 
bound in the resulting 1:1 complex metabolically inactive, preventing the production of 
ROS. Consequently, DFO is able to decrease oxidative stress, alleviating the symptoms 
associated with iron overload disease (Olivieri and Brittenham, 1997). However, the 
DFO-iron chelate is charged and does not readily enter and leave cells.  The high 
hydrophilic nature of DFO limits the membrane permeability and efficiency of this ligand, 
imparting poor absorption from the gastrointestinal tract and a short plasma half-life of 
12 minutes due to rapid drug metabolism (Aouad et al. 2002). As a result, DFO must be 
administered via subcutaneous infusion for extensive periods to achieve a negative iron 
balance, ranging from 8 to 12 h, five to seven times per week at a daily dosage of 20 to 
60 mg/kg (Hershko et al. 2003). Apart from the cumbersome administration route and 
high cost, a third of patients treated with DFO experience pain and swelling at the 
injection site, cumulatively leading to poor patient compliance (Olivieri and Brittenham, 
1997; Wong and Richardson, 2003). Irrespective of its shortcomings, it should be noted 
that DFO use has been credited with producing dramatic strides in survival of 
thalassemia patients. 
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Given the potential problems associated with the prolonged use of DFO, there 
have been numerous attempts to improve its efficacy. These include the generation of a 
high molecular weight form of the chelator coupled to hydroxyethyl starch, lipophilic 
DFO analogs, and libraries of structural DFO analogs (Kalinowski and Richardson 
2005). Unfortunately, the evolution of DFO analogs has not resulted in chelators with 
advantages over the original siderophore. Hence, other orally active alternatives have 
been sought in the quest to develop effective and specific iron chelators. 
Deferiprone 
Deferiprone is an orally active hydroxypyridineone (Figure 4) first used in humans 
in 1987. An advantage of this compound is that the iron(III) chelate of deferiprone 
carries no net charge and therefore can penetrate membranes easily, allowing removal 
of potentially toxic iron from tissues (Neufeld 2006). Deferiprone is available in Europe 
and some other countries but not the United States (Kontoghiorghes et al. 2004). The 
reasons for this difference in availability between countries is not entirely understood but 
may be due to conflicting clinical trials related to the safety and iron clearing efficiency 
of this ligand (Richardson, 2001).  
As deferiprone is bidentate, three molecules are necessary to occupy the 
coordination sites of iron. In biological systems, deferiprone appears to exhibit 
incomplete coordination of iron which would enable access of reductants to the iron 
core and may potentially lead to ROS production (Kalinowski and Richardson 2005). 
Such findings could question the safety of deferiprone, and to overcome this problem 
combination therapy with DFO has been assessed. Deferiprone often causes 
gastrointestinal symptoms and idiosyncratic side effects including erosive arthritis 
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(common in patients in South Asian countries, 5%-20% of patients), neutropenia (up to 
5% of patients), and severe agranulocytosis (up to 0.5% of patients) (Neufeld 2006). 
Thus, close monitoring is required. 
To maintain a negative iron balance in overload patients, deferiprone must be 
administered at a high daily dosage (75 mg/kg/d in 3 divided doses, up to 100 mg/kg) 
(Balfour and Foster, 1999). The limited efficiency of deferiprone is due mainly to 
extensive phase II drug metabolism in the liver where the hydroxyl group, essential for 
chelation and iron clearance, undergoes glucuronidation (Liu and Hider 2002). The 
metabolic inactivation of deferiprone has sparked research into the synthesis of other 
hydroxypyridinones that do not undergo this form of modification in vivo. 
Deferasirox 
Deferasirox (ICL670, Exjade) belongs to a new class of oral tridentate chelators 
N-substituted bis-hydroxyphenyltriazoles (Figure 4), that uses a triazolyl nitrogen and 
two phenolic oxygens as donor groups. This ligand represents one of > 700 compounds 
designed through computer modeling intended for the treatment of transfusional iron 
overload (Nick et al. 2003). Deferasirox is selective for iron (as Fe3+) and binds iron with 
high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper, 
there are variable decreases in the serum concentration of these trace metals after the 
administration of deferasirox. The clinical significance of these decreases is uncertain. 
Deferasirox is orally active with 70% bioavailability and is marketed in the form of tablets 
for oral suspension (Exjade®). It is highly (~99%) protein bound almost exclusively to 
serum albumin and is mainly metabolized in the liver by glucuronidation. With a plasma 
half-life of 8 to 16 hours, once-daily dosing permits circulating drug at all times to 
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scavenge NTBI (Cappellini and Pattoneri 2009). Deferasirox-iron complexes undergo 
enterohepatic recycling and are mainly excreted in the feces (84% fecal, 8% renal). 
Females have a moderately lower apparent clearance (by 17.5%) for deferasirox 
compared to males.  
In addition to its ability to remove NTBI, a recent study has shown that 
deferasirox can also cross the plasma membrane and enter the cell using unknown 
carriers (Glickstein, El et al. 2005; Glickstein, El et al. 2006). Clinical studies have 
demonstrated that after one year , deferasirox produced significant reduction in liver iron 
concentration (Cappellini 2008).  In animal models, deferasirox has been shown to be 5 
times more potent than deferoxamine and 10 times more potent than deferiprone 
(Choudhry and Naithani 2007). 
Deferasirox is indicated for the treatment of chronic iron overload due to blood 
transfusions (transfusional hemosiderosis) in patients 2 years of age and older. The 
recommended initial daily dose of deferasirox is 20 mg/kg body weight. Doses of 
deferasirox should not exceed 30 mg/kg per day since there is limited experience with 
doses above this level. The decision to remove accumulated iron should be 
individualized based on anticipated clinical benefit and risks of deferasirox therapy. In 
patients who are in need of iron chelation therapy, it is recommended that therapy with 
deferasirox be started when a patient has evidence of chronic iron overload, such as the 
transfusion of approximately 100 mL/kg of packed red blood cells (approximately 20 
units for a 40-kg patient) and a serum ferritin consistently >1000 µg/L.  
The most frequently occurring adverse events in the therapeutic studies of 
deferasirox were abdominal pain, nausea, vomiting, diarrhea, and skin rashes. Some 
deferasirox-treated patients also experienced dose-dependent increases in serum 
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creatinine, though most of the creatinine elevations remained within the normal range 
(Cappellini 2005). Serum creatinine should be assessed in duplicate before initiating 
therapy to establish a reliable pretreatment baseline and monitored monthly thereafter. 
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Table 2. Comparison of the main available iron chelators to an ideal chelating 
drug. (modified from Neufeld, 2006) 
 
 Ideal 
Chelator 
Deferoxamine 
1970 
Deferiprone 
1987 
Deferasirox 
2005 
Route of 
administration 
Oral S/C, IV Oral Oral 
 
Plasma t1/2 
Long 
enough to 
prevent 
NTBI 
Short (minutes); 
requires constant 
delivery 
Moderate 
(<2 hr); required 
t.i.d dosing 
Long (8-6 hr); 
remains in 
plasma 24 hr 
Therapeutic index High High Idiosyncratic side 
effects 
High 
 
Chelating efficacy/ 
charge 
High 
Uncharged 
High 
Charged 
Low 
Uncharged 
Moderate 
Uncharged 
 
Side effects 
None Auditory and retinal 
toxicity, effects on 
bone and growth, 
lung toxicity, local 
skin reactions 
Agranulocytosis, 
neutropenia, 
abdominal 
discomfort, 
erosive arthritis 
Abdominal 
discomfort 
rash, mild 
diarrhea 
 
Ability to chelate 
intracellular 
cardiac & other 
tissue iron 
High Lower than 
deferiprone and 
deferasirox 
High in clinical and 
in vitro studies 
Insufficient 
clinical data 
Promising 
laboratory 
studies 
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Figure 4. Chemical structure of the iron chelating agents in clinical use and their 
corresponding iron binding ratio. 
 
2.7 ANIMAL MODELS OF IRON OVERLOAD 
Past efforts to study iron overload and its associated toxicity have been 
hampered by the lack of a suitable experimental model of human iron overload; most 
animal species have a far greater capacity to excrete iron than humans. Recently, the 
Mongolian gerbil (Meriones unguiculatus) was developed as a model of iron overload 
using weekly subcutaneous injections of iron dextran (Carthew, Dorman et al. 1993). 
Studies using the gerbil model have reported that cardiac and hepatic iron content was 
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increased to amounts within the range reported in patients with iron overload (Kuryshev, 
Brittenham et al. 1999). In addition, the gerbil model tends to reproduce critical features 
of the cardiomyopathy found in human iron overload as the gerbil seems unable to 
excrete iron as effectively as other rodents.  In one study, gerbils treated with repeated 
injections of iron dextran over a period of months developed a cardiomyopathy that 
resembles the cardiomyopathy that develops over a period of years in patients with 
chronic iron overload (Kuryshev, Brittenham et al. 1999). Similarly, the accumulation of 
iron in the gerbil heart has been associated with myocyte degeneration and intracellular 
calcification, whereas in the hearts of mice treated identically with iron-dextran that had 
accumulated comparable cardiac iron levels, similar evidence of myocyte damage was 
absent (Yang, Dong et al. 2002). These results suggest that the gerbil model would be 
useful in studying the progression of end organ damage associated with iron-overload.  
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CHAPTER III 
MATERIALS AND METHODS 
 
 This chapter outlines the procedures used for data collection and analysis in the 
present study.  The adult male Mongolian gerbil (Meriones unguiculatus) model of iron 
overload was used.  Iron overload was achieved by multiple intraperitoneal injections of 
iron-dextran. Deferasirox treatment was administered orally at different time points after 
the completion of iron loading. Electrocardiographic and echocardiographic 
measurements were conducted at baseline (before iron loading) and every three 
months thereafter. After the completion of deferasirox treatment, gerbils were sacrificed 
and heart, aorta, liver, kidney and pancreas were excised.  Examination for changes in 
tissue iron concentration, expression of ferritin, and cardiac morphology followed. 
 
3.1 Animal selection and care  
All experiments were conducted using male Mongolian gerbils. Adult male 
Mongolian gerbils (Meriones unguiculatus) were obtained from Charles River 
Laboratories and housed four per cage in an AALAC approved vivarium. Housing 
conditions consisted of a 12h: 12h dark-light cycle with temperature maintained at 22 ± 
2° C. Animals were provided food and water ad libitum.  Gerbils were allowed to 
acclimate to the housing facilities for at least two weeks before experimentation began. 
During this time, the animals were carefully observed. None of the animals exhibited 
signs of failure to thrive, such as precipitous weight loss, disinterest in the environment, 
or unexpected gait alterations. Animal care and procedures were conducted in 
accordance with the Institutional Animal Care and Use Committee of Marshall University 
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using the criteria outlined by the American Association of Laboratory Animal Care 
(AALAC) as proclaimed in the Animal Welfare Act (PL89-544, PL91-979, and PL94-
279). 
 
3.2 Iron loading and chelation 
Gerbils were divided into Control (Ctrl), Iron overload (IO), and iron overload 
followed by deferasirox treatment (IO+DFR). Iron treated animals received 15 
subcutaneous injections of iron dextran (Sigma Chemical, St. Louis, Mo) at a dose of 
100 mg/kg every 5 days for 10 weeks. Deferasirox was administered for one, three, or 
nine months post iron loading. For each treatment group, an age-matched Ctrl and IO 
group was maintained for comparison (Table 3).  
To avoid the stress of chronic, repeated gavage feeding, deferasirox was 
homogenously mixed in plain peanut butter (vehicle) for oral feeding via a 1-mL syringe. 
Deferasirox powder was carefully blended or mixed with creamy, low-fat peanut butter 
and the mixture placed into conical bakery squeeze applicators and delivered into 15-
mL plastic syringes which have had tips cut off.  The mixture was then delivered into 1-
mL syringes with tips removed from which small volumes of the mixture containing the 
desired quantity of drug was carefully introduced into the animal mouths and eaten.  We 
have found that animals acquire a taste for peanut butter after a few days of feeding 
and thereafter eagerly consume the peanut butter. Therefore, the animals were 
adjusted to peanut butter prior to administration of deferasirox-peanut butter mixtures.  
This method of administration is equivalent to giving the drug with food or in 
formulations of drug with filler material. 
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Deferasirox treatment was started 1-week after the last iron dextran injection and 
was given at a single daily dosage of 100 mg/kg. This dosage is based on a previously 
determined dose-response curve of deferasirox in iron overloaded gerbils and 
represents 67% of human values when normalized for body surface area (Wood, Otto-
Duessel et al. 2006). Oral chelator administration gave the animals approximately 0.15 
mL of peanut butter per day. Control and iron overload groups received plain peanut 
butter (vehicle) and were housed, fed, and maintained under identical conditions.  
 
Table 3. Deposition of gerbils in the experimental groups 
Interval Groups n = 10/ group   Treatment   
Baseline Ctrl   10 wk Saline   
IO   10 wk iron   
  Ctrl   10 wk Saline + 1 mo vehicle    
1 months IO  10 wk iron + 1 mo vehicle      IO+ DFR   10 wk iron + 1 mo DFR    
  Ctrl   10 wk Saline + 3 mo vehicle    
3 months IO  10 wk iron + 3 mo vehicle      IO+ DFR   10 wk iron + 3 mo DFR    
  Ctrl   10 wk Saline + 9 mo vehicle    
9 months IO  10 wk iron + 9 mo vehicle      IO+ DFR   10 wk iron + 9 mo DFR    
 
 
3.3 Electrocardiographic procedures 
Gerbils were anesthetized with a ketamine (100 mg/ml)/xylazine (20 mg/ml) 
mixture. EKG recording was performed using standard limb lead system (Biopac)®. To 
emulate lead II, we utilized subcutaneously placed electrodes located in the line with the 
long access of the heart. One electrode (anode) is placed in the upper right quadrant of 
the chest and the other (cathode) in the lower left abdominal wall, just cranial to the 
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groin area. Lead I configuration was performed by placing the cathode and the anode in 
the upper right, and left quadrants of the chest, respectively. Lead III configuration was 
performed by placing the cathode in the upper left quadrant of the chest, while the 
anode was placed in the lower left abdominal wall. 
 
3.4 Transthoracic echocardiography 
Echocardiography is a noninvasive ultrasound procedure in which harmless, 
high-frequency sound waves (frequency >20,000 cycles/sec) are emitted from a 
piezoelectric crystal or transducer, beamed in particular directions, and reflected back 
(echo) by small structures in the mm and sub-mm range. These waves are beamed 
toward and penetrate the heart and are reflected back to the transducer as a series of 
echoes, which are amplified and displayed on a cathode ray tube. It is used to evaluate 
the position, size, and movement of cardiac valves, heart wall structure and function, 
and directional flow of blood within cardiac chambers (Walker, Epling et al. 2007). 
Animals were anesthetized with ip injections of a 2:1 mixture of ketamine HCl (100 
mg/ml) and xylazine (20 mg/ml). Echocardiographic recordings were performed at the 
Cabell Huntington Hospital, Huntington, WV.  Gerbils were shaved in the chest area for 
adequate sonic transference, an ultrasonic transmission gel was applied to the chest 
area, and the animals were positioned on their left sides or backs. Two-dimensional 
echocardiographic measurements, two-dimensional guided M-mode, Doppler M-mode, 
and other recordings from parasternal long- (PLAX) and short-axis (PSAX) views were 
obtained using a Phillips 5500 ECHO system with a 12 MHz transducer. Two-
dimensional measurements were used to image cardiac structures in the parasternal 
long- and short-axis views. The echocardiographic views were then used to position the 
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M-mode echocardiographic line. In the long-axis procedures, the probe was oriented 
toward the base of the heart projecting toward the apex (x-axis) with depth along the y-
axis, thus allowing pulse wave Doppler evaluation of valvular blood flow velocities. In 
the short-axis procedures, the probe was oriented toward the left ventricle and across 
the heart for evaluation of wall structure, which was utilized in the calculation of ejection 
fraction and fractional shortening during systole. M-mode displays were analyzed by a 
digital echocardiographic analysis system. Six measurements were selected for each 
assessment of cardiac structure and function. The structural parameters included 
diastolic (LVSd) and systolic (LVSs) left ventricular septal thickness, diastolic (LVIDd) 
and systolic (LVIDs) left ventricular internal dimension, diastolic (LVPWd) and systolic 
(LVPWs) left ventricular posterior wall thickness, and right ventricular diastolic internal 
dimension (RV). Functional measurements included left ventricular ejection fraction 
(EF), left ventricular fractional shortening during systole (FS), maximal aortic (AVmax), 
pulmonary (PVmax), mitral (MVmax), and tricuspid (TVmax) valvular blood flow velocity. 
Left ventricular ejection fraction (EF), and fractional shortening (FS) were used to 
evaluate systolic function.  
 
3.5 Tissue collection 
Prior to sacrifice, gerbils were anesthetized with a ketamine-xylazine (4:1) 
cocktail (50 mg/kg i.p.) and supplemented as necessary to achieve loss of reflexive 
response. Loss of toe pinch and eye blink reflexes was assessed prior to the initiation of 
any experimental manipulations. Every effort was made to minimize stress and 
discomfort to the animals. 
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 After midline laparotomy, heart, liver, pancreas and aorta were removed and placed in 
Krebs-Ringer bicarbonate buffer (KRB) containing: 118 mM NaCl, 4.7 mM KCl, 2.5 mM 
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 24.2 mM NaHCO3, and 10 mM α-D-glucose 
(pH 7.4) equilibrated with 5% CO2/ 95% O2 and maintained at 37°C. Isolated tissues 
were quickly cleaned of connective tissue, weighed, and immediately snap frozen in 
liquid nitrogen. 
 
3.6 Tissue iron assessment 
After sacrifice, portions of the heart, liver, kidney, pancreas, and aorta were 
isolated, weighed, and sent for quantitative iron (total, heme plus non-heme, tissue iron)  
determination (University of Tampa, Tampa, FL) by inductively coupled plasma-atomic 
emission spectrometry (ICP-AES) (Walker, Epling et al. 2007). Briefly, digestions were 
performed using commercially available trace metal grade HNO3 (ThermoFisher 
Scientific). Dilutions were made with 2% (vol.) HNO3 (trace metal grade) prepared with 
deionized water. All digestion tubes, volumetric pipettes, and volumetric glassware were 
soaked for 24 hours in 2% (vol.) HNO3 (trace metal grade), rinsed four times with 
deionized water, and air dried prior to use. Approximately 300 mg (wet weight) of 
sample was weighed into a glass digestion tube and 6.0 ml of concentrated trace metal 
grade HNO3 added. A 1000 mg/L Yttrium solution in 2% HNO3 (Perkin Elmer), used as 
an internal standard (final concentration 1.67 mg/L), was added to each tube. Samples 
were heated at 37oC for 1 hour and then at 110oC for 2 hours. After digestion, 5.0 ml of 
the clear solution was transferred to a 50 ml volumetric flask and brought to volume with 
2% (vol) HNO3 (trace metal grade). Solutions were filtered through a 0.22 μm syringe 
driven filter unit (Millipore) and analyzed by ICP-AES. A 1.67 mg/L iron solution was 
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used as a control for the digestion procedure. Analyses were performed on a Perkin 
Elmer ICP-AES (Optima 2100 DV) using a 0 to 1 mg/L, 0 to 10 mg/L, or 0 to 100 mg/L 
(for iron only) standard curve, depending upon iron concentration. Calibration and 
control solutions for the 0 to 1 mg/L and 0 to 10 mg/L standard curves were prepared 
from a multi-element standard (ICP Multi-element Solution 2, Spex Chemicals, 10 
mg/L). Calibration and control solutions for the 0 to 100 mg/L standard curve were 
prepared from a 1000 mg/L iron standard solution (Perkin Elmer).  All calibrators and 
controls contained an internal Yttrium standard. The measurements for iron (238.204 
nm) were conducted in the axial mode. Sample concentrations were determined from 
standard curves generated by linear regression analysis. The minimal detectable 
concentration for each metal was determined using the mean plus the three-fold 
standard deviation obtained from 10 blank digestions.  
 
3.7 Histological analysis 
Whole hearts (breadloaf sectioned) and representative sections of liver, 
pancreas, and aorta were fixed in 10% buffered formalin solution, and processed into 
paraffin blocks by routine procedures. Samples were then sectioned (8 μm) with a 
cryostat and sections were mounted on poly-lysine (Sigma, St. Louis, MO) coated 
slides. Sections were stained with Prussian blue iron stain. Slides were evaluated by 
light microscopy and images were taken at 200X, or 400X. This data was collected and 
reviewed in a blinded fashion. 
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3.8 SDS-PAGE and immunoblotting  
Tissue was pulverized in liquid nitrogen using a mortar and pestle until a fine 
powder was obtained.  After washing with ice cold PBS, samples were lysed on ice for 
15 minutes in T-PER (2 mL/1 g tissue weight) and centrifuged for 10 minutes at 12000 x 
g.  The supernatant was collected and the protein concentrations of homogenates were 
determined in triplicate via the Bradford method (Pierce) using bovine serum albumin as 
a standard. Samples were solubilized at a concentration of 3 mg/ml in SDS-loading 
buffer and boiled for 5 minutes.  Sixty µg of protein from each sample was separated on 
10% SDS-PAGE gels and then transferred onto Hybond nitrocellulose membranes 
using standard conditions. To verify transfer of proteins and equal loading of lanes, the 
membranes were stained with Ponceau S.  Membranes were blocked in buffer (5% 
nonfat dry milk in tris-buffered saline with 0.1% Tween-20 (TBST) for 1 hour at room 
temperature, washed (TBST, 3 X 5 minutes), and incubated in primary antibody (1:1000 
dilution) in TBST with 5% milk overnight at 4ºC.  After washing (TBST, 3 X 5 minutes), 
membranes were incubated in horseradish peroxidase HRP-linked anti-biotin and the 
appropriate secondary antibody (1:1000 dilution) in TBST with 5% milk for 1 hour at 
room temperature, then rewashed (TBST, 3 X 5 minutes).  Proteins were visualized by 
ECL and quantified by densitometry.  Exposure times were adjusted to keep the 
integrated optical densities (IOD) of the film within a linear and nonsaturated range.  
Specificity of the bands was assessed by comparison of molecular weight markers and 
positive controls.  To allow direct comparisons to be made between the expression 
levels of different signaling molecules and the amount of protein present, immunoblots 
were stripped with Restore western blot stripping buffer and reprobed as detailed by the 
manufacturer.  After verifying the absence of residual HRP activity, membranes were 
 
 
-49- 
 
washed and reprobed for other proteins.  All membranes were probed for GAPDH for 
analysis and loading control.  
 
3.9 Oxidative fluorescent microscopy 
Cardiac or hepatic specimens were serially sectioned (8 μm) using an IEC 
Minotome cryostat and collected on poly-lysine coated slides. Hydroethidine (HE), an 
oxidative fluorescent dye, was used to visualize superoxide (O2•–) production in situ 
(Miller, Gutterman et al. 1998; Lund, Faraci et al. 2000). Hydroethidine freely permeates 
the cells and, in the presence of O2•–, is oxidized to ethidium bromide, which is trapped 
by intercalating with the DNA (Rothe, Emmendorffer et al. 1991). Because ethidium 
bromide is impermeable to cell membranes, extracellular O2•– would not be expected to 
contribute significantly to the observed cellular fluorescence. Neither hydroxyl radical, 
nitric oxide radical, peroxynitrite, hydrogen peroxide, hypochlorite, nor singlet oxygen 
significantly oxidize hydroethidine; as such, an increase in ethidium bromide 
fluorescence is thought to indicate O2•– generation specifically within the fluorescing 
cell. Heart sections were stained with hydroethidine and visualized under fluorescence 
as described previously (Rice, Preston et al. 2006). The intensity of fluorescent ethidium 
bromide-stained nuclei was calculated by digitizing images and then determining the 
average pixel intensity of six randomly positioned regions (1000 μm2) per cross section. 
Morphometric evaluation was performed with the use of a computerized imaging 
analysis system (Olympus MicroSuite™ Basic). 
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3.10 Oxidized Protein Analysis  
Cardiac and hepatic protein isolation was conducted as described above. To 
identify carbonyl groups that are introduced into the amino acid side chain after 
oxidative deamination of proteins, oxyblot analysis was performed. The level of protein 
oxidation was determined by an Oxidized Protein Detection Kit (Oxyblot, Chemicon 
Cat# S7150-Kit). Oxyblot kit derivatizes carbonyl groups to a 2, 4-
dinitrophenylhydrazone (DNP) moiety. The DNP moiety can then be detected using 
anti-DNP antibodies and is a method to assay for one form of oxidative damage to a 
protein. The proteins are derivatized as per the protocol given in the kit. These proteins 
are separated on 10% SDS-PAGE gels and transferred onto nitrocellulose membrane. 
After the transfer, membranes were blocked with 2.5% BSA in Tris Buffered Saline 
(TBS) with 0.2% Tween-20 for 1 hour at room temperature. The nitrocellulose 
membrane was exposed to a primary rabbit anti-DNPH protein antibody from Chemicon 
Oxyblot (1:200 working dilution) for 1 hour, and then to a secondary antibody (Goat 
Anti-Rabbit IgG (HRP-conjugated) diluted in the blocking solution 1:500 for 1 hour at 
room temperature. Membranes were washed after every step in washing buffer (TBS 
with 0.2% Tween-20). Protein bands were visualized with ECL (Amersham 
Biosciences). Band signal intensity was quantified by densitometry using a flatbed 
scanner (Epson Pefection 3200 PHOTO) and Imaging software (AlphaEaseFC). 
 
3.11 In situ cell death detection (TUNEL) 
Liver samples were cut into serial 8μm sections using an IEC Minotome Cryostat.  
After fixing with 4% paraformaldehyde, sections were washed with phosphate-buffered 
saline (PBS, pH7.4), and then permeabilized with 0.1% sodium citrate and 0.1% Triton 
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X-100. DNA fragmentation was determined by TdT-mediated dUTP nick end labeling 
(TUNEL) as suggested by the manufacturer’s recommendations.  Cross-sections from 
each liver were treated with DNase I to induce DNA fragmentation as a positive control.  
Three randomly selected regions from each cross section were visualized by 
epifluorescence using an Olympus fluorescence microscope (Melville, NY) fitted with a 
40X objective.  Images were recorded digitally using a CCD camera (Olympus, Melville, 
NY), and the samples were analyzed by counting positively stained nuclei with DAPI 
nuclear staining for contrast.  
  
3.12 Statistical analysis 
Results are presented as mean ± SEM.  Data were analyzed by using SigmaStat 
3.0 computer software.  One-way (or two-way) analysis of variance (ANOVA) was used 
for overall comparisons where appropriate with the Student-Newman-Keuls post hoc 
test used to determine statistical significance. The level of significance accepted a priori 
was P ≤ 0.05. 
 
3.13 Materials 
Deferasirox powder used in the study was provided by Novartis Pharmaceuticals 
(East Hanover, NJ). Primary antibodies against P-ERK1/2 MAPK (Thr202, Tyr204) (cat 
#9106), p-p38 MAPK (Thr180, Tyr182) (cat#9216), p-JNK (Thr183, Tyr185) (cat #9251), 
ERK1/2 MAPK (cat #9102), p38 MAPK (cat #9218), JNK (cat #9252), caspase-3 
(#9662), anti-biotin as well as anti- mouse and -rabbit secondary antibodies, and NIH 
3T3 cell lysates were obtained from Cell Signaling Technology (Beverly, MA). Anti-Bax 
(N-20) (sc-492), Bcl-2(C-2) (sc-7382), and Bad (H-168) (sc-7869), ferritin heavy chain 
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(H-53) (cat #25617) and anti-goat secondary antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA).  The TUNEL assay kit was purchased from Roche 
Diagnostics Corporation (Indianapolis, IN).  Precast 10% and 15%  SDS-PAGE gels 
were procured from Cambrex Biosciences (Baltimore, MD) while the enhanced 
chemiluminescence (ECL) Western blot detection reagents, Hyperfilm, and Hybond 
nitrocellulose membranes came from Amersham Biosciences (Piscataway, NJ).  
Restore western blot stripping buffer and T-PER tissue lysis buffer were obtained from 
Pierce (Rockford, IL).  Dual Color molecular weight markers were from BioRad 
(Hercules, CA).  All other chemicals were purchased from Sigma (St. Louis, MO).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-53- 
 
CHAPTER IV 
RESULTS 
 
The results chapter will be subdivided into three articles.  Each article will deal 
specifically with a specific aim of the dissertation project. 
Note: The method section has been omitted from these articles to avoid redundancy. 
Please refer to Chapter III for detailed materials and methods. 
 
Article #1: Corresponds to Specific Aim #1 
To determine if deferasirox is able to reduce cardiac iron content, iron-induced 
ferritin upregulation, and iron-related increases in indices of oxidative stress such 
as superoxide overproduction, protein oxidation, and the phosphorylation of the 
extracellular regulated kinase 1/2 (ERK1/2)-, p38-, and c-Jun N-terminal kinase 
(JNK)-mitogen activated protein kinases (MAPKs). 
 
 
 
  
 
 
-54- 
 
DEFERASIROX REMOVES CARDIAC IRON AND ATTENUATES OXIDATIVE 
STRESS IN THE IRON-OVERLOADED GERBIL 
Rabaa M. Al-Rousan1, Satyanarayana Paturi2,3, Joseph P. Laurino4, Sunil K. Kakarla1, 3 
, Anil K. Gutta2, 3, Ernest M. Walker3, 5, and Eric R. Blough1, 2 
1Department of Pharmacology, Physiology, and Toxicology, Joan C. Edwards School of 
 Medicine, Marshall University, Huntington, WV; 2Department of Biological Sciences, 
 Marshall University, Huntington, WV; 3 Cell Differentiations and Development Center, 
 Marshall University, Huntington WV; 4Department of Chemistry, University of Tampa, 
 Tampa, FL; 5Department of Pathology, Joan C. Edwards School of Medicine, Marshall 
 University, Huntington, WV 
 
 American Journal of Hematology, 84:565–570, 2009.  
 
  
 
 
-55- 
 
Abstract 
 
Iron-induced cardiovascular disease is the leading cause of death in iron-
overloaded patients. Deferasirox is a novel, once daily oral iron chelator that was 
recently approved for the treatment of transfusional iron overload. Here, we investigate 
whether deferasirox is capable of removing cardiac iron and improving iron-induced 
pathogenesis of the heart using the iron overload gerbil model. Animals were randomly 
divided into three groups: control, iron overload, and iron overload followed by 
deferasirox treatment. Iron-dextran was given 100 mg/kg per 5 days i.p for 10 weeks. 
Deferasirox treatment was started post iron loading and was given at 100 mg/kg/day p.o 
for 1- or 3- months. Cardiac iron concentration was determined by inductively coupled 
plasma atomic emission spectroscopy. Compared with the untreated group, deferasirox 
treatment for 1- and 3- months decreased cardiac iron concentration 17.1% (P = 0.159) 
and 23.5% (P < 0.05), respectively. These treatment-associated reductions in cardiac 
iron were paralleled by decreases in tissue ferritin expression of 20% and 38% at 1 and 
3 months, respectively (P < 0.05). Using oxyblot analysis and hydroethidine 
fluorescence, we showed that deferasirox significantly reduces cardiac protein oxidation 
and superoxide abundance by 47.1% and 36%, respectively (P < 0.05). Iron-induced 
increase in oxidative stress was also associated with increased phosphorylation of 
ERK1/2-, p38-, and JNK-mitogen-activated protein kinases (MAPKs). Interestingly, 
deferasirox treatment significantly diminished the phosphorylation of all three MAPK 
subfamilies. These results suggest that deferasirox may confer a cardioprotective effect 
against iron induced injury. 
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Introduction 
Excessive body iron or iron overload in thalassemia and other conditions is a 
serious health issue the world over (Hershko 2007). Increased cardiac iron deposition is 
the leading cause of morbidity and mortality in transfusion-dependent patients as these 
conditions are oftentimes associated with diastolic dysfunction, arrhythmias, and dilated 
cardiomyopathy (Walker, Epling et al. 2007). The mechanism(s) by which increased iron 
affects cellular function are not well understood; however, increases in reactive oxygen 
species (ROS) have been posited to be involved as current data has suggested a 
strong link between elevations in cardiac ROS levels and cardiac dysfunction (Oudit, 
Trivieri et al. 2004).  
In the past, iron overload was treated with deferoxamine and deferiprone, 
although effective, treatment compliance was frequently compromised as the 
administration of these compounds is often burdensome or associated with serious side 
effects (Hershko, Link et al. 2005; Neufeld 2006). Deferasirox is a recently approved, 
orally administered tridentate iron chelator that is administered on a once-daily regimen 
(Vichinsky 2008). Initial findings regarding the use of deferasirox have suggested that 
this chelator is very effective in removing liver iron, while other data have suggested that 
deferasirox may be effective in diminishing cardiac iron (Rachmilewitz, Weizer-Stern et 
al. 2005; Pennell, Porter et al. 2008; Pennell, Sutcharitchan et al. 2008). The primary 
objective of this investigation was to determine if chronic administration of deferasirox is 
capable of removing excess iron from the heart in the gerbil model of iron overload. We 
hypothesized that deferasirox would reduce cardiac iron content and that this reduction, 
if present, would be associated with diminished cardiac ROS.  
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Results 
Characterization of animals 
Total body and liver weights were obtained and compared. All animals tolerated 
the iron loading and chelation without any apparent ill effects. The body weights of iron 
overloaded gerbils were similar to controls, indicating that the injection of iron dextran 
did not result in debilitation or weight loss. Heart/ body weight ratio was ~20% higher in 
the IO group compared to the Ctrl group (P < 0.05) (Table 4). No significant difference 
was observed after one or three months of follow up or with deferasirox treatment. 
 
Table 4. Deposition of gerbils in the experimental groups and heart/body weights. 
Interval 
Groups 
n = 10/ group 
Treatment       Heart/ body wt (%) 
Baseline 
Ctrl 10wk saline 0.41 ± 0.04 
IO 10wk iron         0.49 ± 0.02* 
 
Ctrl 10 wk saline + 1mo vehicle 0.42 ± 0.01 
1 months IO 10 wk iron + 1 mo vehicle 0.43 ± 0.01 
 
IO+ DFR 10 wk iron + 1 mo DFR 0.42 ± 0.01 
 
Ctrl 10 wk saline + 3 mo vehicle 0.38 ± 0.01 
3 months IO 10 wk iron + 3 mo vehicle          0.39 ± 0.01 
 
IO+ DFR 10 wk iron + 3 mo DFR 0.38 ± 0.01 
An asterisk (*) indicates significant difference from age matched control  
 
Cardiac iron levels 
Cardiac iron levels were measured using inductively coupled plasma atomic 
emission spectrometry (ICP-AES). Compared to hearts obtained from control animals, 
iron overload increased cardiac iron level by 10.4 fold (P < 0.05). Cardiac iron levels 
were 8.1- and 7.4-fold higher than that of the corresponding age-matched controls at 
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one and three months of follow up, respectively (P < 0.05). Compared to the 3 month-IO 
group, deferasirox treatment decreased cardiac iron levels by 23.5% (P < 0.05) (Figure 
5). Prussian blue staining demonstrated elevated iron deposition in cardiac sections 
from gerbils in the 3 month-IO group (Figure 6). Iron deposition exhibited a 
nonhomogenous distribution with a higher deposition in the ventricle compared to atria. 
In the left ventricular wall, iron accumulation was higher in the epicardium and 
endocardium, and was the least in the myocardium. Within the myocardium, iron tended 
to accumulate in the interstitium although deposition was clearly visible inside the 
myocytes. Deferasirox treatment for three months produced a notable decrease of 
stainable iron visible in all regions of the heart (Figure 6).  
 
 
Figure 5. Average iron levels in mg/g tissue weight in cardiac tissue of gerbils in 
the experimental groups. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload 
followed by deferasirox treatment, 1m: 1 month interval, 3m: 3 months interval. (*) 
indicates significant difference from control, (†) indicates significant difference from iron 
overload group (P < 0.05).                           
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Figure 6. Histological examination of left ventricular myocardium of Ctrl (A), IO 
(B), and IO+DFR (C) gerbils followed for 3 months. Ferric iron was detected by 
Prussian blue staining. No apparent iron deposition was observed in control gerbils. Iron 
overload resulted in iron accumulation in endothelial cells in cardiac interstitium and to a 
lesser extent in cardiac myocytes. Deferasirox treatment diminished iron deposition 
from all regions of cardiac tissue. Bar represents 100 µm, Images were taken at 400X 
original magnification. 
 
 
Ferritin protein expression 
Cardiac ferritin protein levels were analyzed by immunoblot using total protein 
isolates from each of the experimental groups. Compared to control animals, ten weeks 
of iron overload increased ferritin protein by 1.9 fold (P < 0.05) (Figure 7). After 
completion of iron loading ferritin levels remained elevated and were  1.7 and 1.6 fold 
higher than that of the corresponding age-matched control after one and three months 
of follow up, respectively (P < 0.05). Deferasirox treatment significantly reduced cardiac 
ferritin expression by 20% and 38% after one (1m-IO+DFR) and three months (3m-
IO+DFR) of treatment, respectively (P < 0.05). 
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Figure 7. Effect of iron overload and iron chelation on ferritin heavy chain (FerH) 
protein expression in cardiac tissue of gerbils in the experimental groups. (Upper 
panel) Results were obtained from six experiments in each group and expressed as a 
percentage of the corresponding age matched control value. (Lower panel) 
Representative Western blot analysis. Ctrl: control, IO: Iron overload, IO+ DFR: Iron 
overload followed by deferasirox treatment, 1m: 1 month interval, 3m: 3 months interval.  
(*) indicates significant difference from control, (†) indicates significant difference from 
iron overload group (P < 0.05). 
 
 
Superoxide abundance 
Because increased iron accumulation has been found to be associated with 
increased oxidative stress, we examined cardiac tissue sections from Ctrl, IO, and 
IO+DFR groups from 3 months interval for superoxide generation using HE 
fluorescence. Compared to 3 months-Ctrl, a 101% increase in HE fluorescence was 
observed in the 3 months-IO groups (P < 0.05). Three months of deferasirox treatment 
(3mIO+DFR) resulted in 36% reduction in HE fluorescence (P < 0.05) (Figure 8). The 
overall distribution of superoxide abundance appears to be similar in all regions of the 
cardiac myocardium (Figure 8).  
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Figure 8. Detection of cardiac superoxide by dihydroethidium in Ctrl, IO, and 
IO+DFR groups. (Upper panel) The increase in superoxide involves all layers of 
ventricular wall. Bar represents 100µm, images were taken at 400X original 
magnification. (Lower panel) Quantification of cardiac superoxide as determined by 
intensity of fluorescent ethidium bromide-stained nuclei from six animals in each group. 
3m = 3 months interval. An asterisk (*) indicates significant difference from control 
animals, (†) indicates significant difference from iron overload (P < 0.05). 
 
Protein oxidation 
To investigate whether iron overload modifies cardiac proteins, we next 
examined protein isolates obtained from the hearts of Ctrl, IO, and IO+DFR for three 
months for the presence of carbonylated protein using OxyBlot™ detection kit. Protein 
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carbonylation was increased by 114% in the 3 month-IO group compared to that of 
3months-Ctrl (P < 0.05). These levels were reduced by 47% after three months of 
deferasirox treatment (3mIO+DFR) (P < 0.05) (Figure 9).   
 
 
Figure 9. Effect of iron overload or deferasirox treatment on cardiac protein 
carbonylation. (Left) Representative oxyblots of cardiac protein isolates from ctrl, IO, 
and IO+DFR from 3 months interval. (Right) Quantification of oxidatively modified 
proteins in the corresponding groups. 3m = 3 months interval. An asterisk (*) indicates 
significant difference from control animals, (†) indicates significant difference from iron 
overloaded animals (P < 0.05). 
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Determination of ERK1/2-, p38-, and JNK-MAPK phosphorylation 
The MAPK pathway has been identified as an important signaling cascade 
involved in the control of cell growth, differentiation, and adaptation whose activity is 
thought to be regulated, at least in part by cellular ROS levels (Martindale and Holbrook 
2002). No significant difference in ERK1/2, P38, or JNK-MAPK protein expression was 
observed between groups. ERK1/2-MAPK phosphorylation was 67%, 50%, and 58% 
higher in the IO, 1 month-IO, 3 months-IO groups compared to the corresponding age 
matched control, respectively (P < 0.05). Deferasirox treatment for one or three months 
significantly reduced ERK1/2 phosphorylation by 13% and 32%, respectively (P < 0.05) 
(Figure 10A). p38-MAPK phosphorylation was 164%, 218%, and 134% higher in the IO, 
1 month-IO, 3 month-IO groups compared to the corresponding age-matched control, 
respectively. Similar to our findings for ERK1/2, the phosphorylation of p38-MAPK was 
decreased 33% and 46% after one and three months of deferasirox treatment, 
respectively (Figure 10B). Likewise, JNK-MAPK phosphorylation, was 52%, 50%, and 
98% higher in the IO, 1 month-IO, 3 month-IO groups compared to the corresponding 
age-matched control, respectively (P < 0.05) (Figure 10C). Deferasirox treatment 
significantly reduced the phosphorylation of JNK-MAPK by 27%, and 47% after one and 
three months of chelation, respectively (P < 0.05) (Figure 10C).  
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Figure 10. Effect of iron overload or deferasirox treatment on the expression of 
total and phosphorylated ERK1/2-, P38-, and JNK-MAPKs. (Left) Representative 
western blot demonstrating the expression of total and phosphorylated ERK1/2-, P38-, 
and JNK-MAPK in the hearts in the experimental groups. (Right) Quantification of 
protein expression of p-ERK1/2- (A), p-P38- (B), p-JNK-MAPKs (C) in the 
corresponding groups. Results are expressed as a percentage of the corresponding age 
matched control value. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload followed 
by deferasirox treatment, 1m: 1 month interval, 3m: 3 months interval.  (*) significantly 
different from control group; (†) significantly different from iron overload group (P < 0 
.05).  
 
Discussion  
The accumulation of cardiac iron is a complication of iron overload in transfusion-
dependent patients that if allowed to proceed unchecked can lead to cardiac 
arrhythmias and heart failure (Wood, Otto-Duessel et al. 2006). This study 
demonstrated that oral deferasirox administration significantly reduces cardiac iron 
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levels in the iron-overloaded Mongolian gerbil. In addition, our data demonstrates that 
these deferasirox-induced decreases in cardiac iron were associated with diminished 
indices of cardiac reactive oxygen species (ROS), and decreased activation of MAPK 
signaling.  
Deferasirox decreases cardiac iron and ferritin levels in the iron overloaded gerbil 
The similarities of iron accumulation, distribution, and associated pathology in 
gerbil and human hearts have suggested that the Mongolian gerbil iron-overload model 
may mimic many of the events seen in the iron-overloaded human (Kaiser, Davis et al. 
2003). Our findings demonstrated that iron loading for ten weeks resulted in a 10.4 fold 
increase in cardiac iron concentration (Figure 5). Although decreasing slightly, tissue 
iron concentration in the iron overloaded animals remained elevated one- (8.1 fold) and 
three- (7.4 fold) months following discontinuation of iron administration. Three months of 
oral deferasirox treatment significantly reduced cardiac iron concentration by 23.5% 
compared to the corresponding untreated group (Figure 5). This decrease in tissue iron 
levels with treatment was consistent with previous reports that have used a similar 
duration of iron loading and deferasirox treatment (Wood, Otto-Duessel et al. 2006; 
Otto-Duessel, Aguilar et al. 2007; Walker, Epling et al. 2007). For example, Wood and 
colleagues (2006) have demonstrated that deferasirox treatment for 12 weeks reduced 
cardiac iron content 20.5%. In an effort to expand upon these findings, we also 
performed Prussian blue iron staining of cardiac tissue sections. As expected, and 
similar to previous studies (Otto-Duessel, Aguilar et al. 2007; Otto-Duessel, Brewer et 
al. 2008), we observed increases in cardiac iron deposition with iron overload and what 
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appears to be a similar reduction in the amount of tissue iron following deferasirox 
treatment (Figure 6).  
To explore the effect of deferasirox on iron overload further, we also examined 
the regulation of ferritin protein levels in the heart. Ferritin is the major iron-storage 
protein at the cellular and organismal level. The ferritin protein is typically increased with 
iron overload (Tran, Eubanks et al. 1997) as this molecule is thought to be responsible 
for the sequestration of potentially harmful, reactive iron (de Valk and Marx 1999). Using 
immunoblotting, we demonstrate that iron-overload was associated with a robust 
induction of ferritin protein in the heart (Figure 7). As predicted from our ICP-AES data, 
we further demonstrate that deferasirox treatment significantly decreased cardiac ferritin 
levels (Figure 7). Taken together, these results are consistent with the notion that oral 
deferasirox administration is capable of reducing cardiac iron.  
Reduced cardiac iron levels are associated with decreases in tissue ROS 
Excess "labile iron" is potentially detrimental to the cell because of its propensity 
to participate in oxidation-reduction reactions that generate harmful free radicals (Deb, 
Johnson et al. 2009). In addition, it is also thought that a chronic elevation in tissue iron 
levels can lead to depletion of antioxidants which, if not restored, can by itself lead to 
further ROS elevation and provide a mechanism for further dysfunction (Eaton and Qian 
2002; Oudit, Trivieri et al. 2004). Whether exogenous antioxidant supplementation can 
be used to prevent such changes remains to be determined. For example, previous 
reports using selenium and vitamin E, but not taurine, failed to show improvement in 
indices of oxidative stress in gerbil (Otto-Duessel, Aguilar et al. 2007).  Although the 
physiological effects of reduced superoxide levels following iron chelation were not 
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investigated in the present study, it has been previously demonstrated that excess 
superoxide can result in the production of iron-catalyzed hydroxyl radicals (Bartfay, 
Dawood et al. 1999; de Valk and Marx 1999) and mitochondrial dysfunction (Afanas'ev 
2005). Whether these events are occurring in the current study and if they are 
diminished by iron chelation is not clear.   
To explore other ROS-related effects of iron overload and iron chelation, we also 
examined protein oxidation by determining the amount of protein carbonylation. Our 
data demonstrate that iron-overload was associated with increased levels of protein 
oxidation in the heart (Figure 9) and importantly, that deferasirox treatment is capable of 
decreasing the amount of oxidized proteins in the iron overloaded gerbil heart. Although 
the physiological effects of protein oxidation in the heart are not entirely elucidated, 
recent work has suggested that protein oxidation can alter protein function and 
conformation (Crowder and Cooke 1984; Hertelendi, Toth et al. 2008).  
Reduced cardiac iron levels are associated with decreases in iron-associated MAPK 
phosphorylation 
Recent data has suggested that increased ROS levels can trigger the activation 
of multiple signaling pathways including mitogen-activated protein kinases (MAPKs) 
(Martindale and Holbrook 2002). In addition, several lines of evidence have indicated 
that the MAPK proteins may be involved in cardiovascular remodeling and that the 
phosphorylation (activation) of these proteins is associated with the development of 
cardiac hypertrophy (Molkentin 2004; Wenzel, Muller et al. 2005). Here, we 
demonstrate that iron overload was associated with increased MAPK phosphorylation 
and that this effect was reversed following deferasirox treatment (Figure 10). These 
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data are consistent with previous work of Dai and colleagues who demonstrated in 
primary hepatocytes that increased intracellular iron was associated with increased 
ERK1/2- and p38-MAPK phosphorylation (Dai, Huang et al. 2004). Whether the 
observed changes in MAPK phosphorylation are directly related to changes in tissue 
iron concentration, indices of tissue ROS or other factors is not known and cannot be 
determined from the present study design. Nonetheless, it is interesting that tissue iron 
levels appeared to affect each of the MAPK proteins differently. For example, 
phosphorylated ERK1/2 levels appeared to be maximal directly after completion of the 
iron loading while conversely, the phosphorylation of the p38- and JNK-MAPK proteins 
was not maximal until one and three months of iron overload, respectively. Furthermore, 
the magnitude of p38-MAPK phosphorylation appears to be greater than that seen for 
either ERK1/2- or JNK-MAPK,  possibly suggesting that p38-MAPK phosphorylation in 
the heart may be more sensitive to increased iron (or stress) than either the ERK1/2 or 
JNK proteins.  
In summary, the present study demonstrates an important in vivo association 
between iron chelation, oxidative stress, and MAPK phosphorylation. Whether the 
observed changes may relate or contribute to complications seen in transfusional iron 
overload is currently unclear.  Further, the effect of alternative treatment regimens is not 
clearly understood. Otte-Duessel et al. (2007) have suggested that twice-daily dosing of 
deferasirox appears to improve cardiac iron elimination compared to that observed 
using single daily dosing protocol. In addition, the administration of deferasirox in 
combination with deferoxamine produced no additive effect on the cardiac iron levels 
above that observed with deferasirox alone (Otto-Duessel, Aguilar et al. 2007). Whether 
this effect is due to limitations in the gerbil model itself (Otto-Duessel, Aguilar et al. 
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2007) or is applicable to other models remains to be determined. As such, clinical 
implications have to be evaluated carefully. Better understanding of the how cardiac iron 
levels may affect tissue ROS and function will no doubt be useful to improving clinical 
guidelines for cardioprotection.  
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Article #2: Corresponds to Specific Aim #2 
To determine if deferasirox is able to reduce hepatic iron content, iron-induced 
ferritin upregulation, and iron related increases in indices of oxidative stress and the 
effect of these changes, if present, on  the incidence of  iron-related changes in cell 
death and apoptotic signaling. 
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Abstract 
Iron overload is associated with an increased risk of developing liver 
complications including fibrosis, cirrhosis, and hepatocellular carcinoma. Deferasirox is 
a novel oral chelator with high iron-binding potency and selectivity. Here, we investigate 
the ability of deferasirox to remove excessive hepatic iron and prevent or reverse iron 
induced hepatic injury.  Adult male Mongolian gerbils were randomly divided into three 
groups: control, iron overload, and iron overload followed by deferasirox treatment. Iron 
overload animals received iron dextran 100 mg/kg i.p /5 d for 10 wks while deferasirox 
was given 100 mg/kg/d p.o for 1 or 3 months. Compared to the non-treated iron 
overload group, deferasirox treatment reduced hepatic iron levels by 43.5% after three 
months of treatment (P < 0.05). Histological analysis detected frequent iron deposition, 
evidence of hepatic damage, and lipid accumulation in hepatic tissue of the iron 
overloaded group. Iron deposition was significantly diminished with deferasirox 
treatment and no evidence of lipid accumulation was observed. Immunoblotting 
demonstrated that iron overload caused about a two fold increase in hepatic ferritin 
expression (P < 0.05), which was reduced by 47.5% following three months of 
deferasirox treatment (P < 0.05). In addition, deferasirox significantly reduced hepatic 
protein oxidation and superoxide abundance. The percentage of TUNEL-positive nuclei 
in the deferasirox treated livers was 41.0% lower than that of the iron overloaded group 
(P < 0.05). Similarly, iron related increase in the expression of Bax/Bcl-2, Bad, and 
caspase-3 were significantly lower following deferasirox treatment. These findings 
suggest that deferasirox may confer protection against iron induced hepatic toxicity. 
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Introduction 
Iron overload is associated with liver, pancreatic, and cardiac dysfunction and is 
potentially deadly if improperly managed (Gordeuk, Bacon et al. 1987). The incidence of 
iron overload appears to be increasing, and it has been estimated that this disorder now 
afflicts over 100 million worldwide (Kontoghiorghes 2006). Most often, iron overload is 
seen in those with hereditary hemochromatosis and in individuals that must undergo 
frequent blood transfusions (Gordeuk, Bacon et al. 1987). The etiology of iron overload 
is thought to be governed by the magnitude of the body iron burden, the rate at which 
the increase in body iron has occurred, and  the distribution of the excess iron within the 
body (Kushner, Porter et al. 2001). The management of iron overload may be achieved 
by pharmacologic chelating agents such as deferoxamine, deferiprone, and Deferasirox 
(Olivieri and Brittenham 1997). Deferoxamine (DesferalR) is presently the standard of 
care for the first-line treatment of transfusional iron overload (Brittenham, Griffith et al. 
1994). Although effective in removing iron, treatment compliance is oftentimes 
compromised given that deferoxamine administration requires overnight subcutaneous 
infusions, 5-7 nights/week (Hershko, Link et al. 2005; Neufeld 2006). In contrast to the 
burden associated with deferoxamine treatment, deferasirox (ExjadeR, ICL670) is given 
orally using a once-daily regimen. Although initial findings have been very promising, 
information regarding the effect of deferasirox on hepatic iron handling is lacking.  
It is thought that the toxic effect of iron is due, at least in part, to the generation of 
reactive oxygen species (ROS) through the Fenton reaction where iron mediates the 
oxidation of free radical intermediates such as superoxide anion (O2•–) or hydrogen 
peroxide (H2O2) to highly toxic free radicals such as hydroxyl radical (HO•) (Storz and 
Imlay 1999). Here, we investigate whether deferasirox is capable of removing excess 
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iron from liver and the effect of iron removal, if present, on hepatic ROS. We 
hypothesized that deferasirox treatment would reduce hepatic iron content and that this 
decrease in iron would be associated with decreases in ROS that will, in turn, be 
strongly associated with the reversal or reduction of iron-induced changes in hepatic 
structure and function. 
 
Results 
Characterization of animals 
  Total body and liver weights were obtained and compared .  All animals tolerated 
the iron loading and chelation without any apparent ill effects. The body weights of iron 
overloaded gerbils were similar to controls, indicating that the injection of iron dextran 
did not result in debilitation or weight loss. Liver weights were increased 52% after 10 
weeks of iron overload and remained elevated after one and three months follow up (P 
< 0.05) (Table  5). Deferasirox treatment was effective in reducing iron-associated 
increases in whole liver weight (Table 5). 
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Table 5. Deposition of gerbils in the experimental groups and liver/body weights. 
Interval 
Groups 
n = 10/ group 
Treatment Liver/ body wt (%) 
Baseline 
Ctrl 10wk saline 3.10 ± 0.17 
IO 10wk iron 4.72 ± 0.21* 
 
Ctrl 10 wk saline + 1mo vehicle 3.71 ± 0.14 
1 months IO 10 wk iron + 1 mo vehicle 5.77 ± 0.21* 
 
IO+ DFR 10 wk iron + 1 mo DFR 5.20 ± 0.17*+ 
 
Ctrl 10 wk saline + 3 mo vehicle 3.63 ± 0.08 
3 months IO 10 wk iron + 3 mo vehicle 5.47 ± 0.20* 
 
IO+ DFR 10 wk iron + 3 mo DFR 4.51 ± 0.15*+ 
An asterisk (*) or cross (+) indicates significant difference from age matched control or 
iron overload groups, respectively. 
 
Hepatic iron levels 
Hepatic iron levels were elevated 90 fold compared to age matched controls after 
iron overload injections (P < 0.05). Hepatic iron levels exhibited gradual reduction to  
76.5 and 57.8 fold at one month and three months post overload, respectively (P < 
0.05). Deferasirox treatment decreased hepatic iron level by 43.5% after three months 
of treatment (P < 0.05) (Figure 11). These observations were consistent with hepatic 
Prussian blue staining results in which iron overloaded hepatic tissue exhibited 
frequently elevated iron deposits in all regions of the hepatic plate but especially 
concentrated in the periportal region (Figure 12, C). Interestingly, deferasirox produced 
striking hepatocyte clearing from all regions of hepatic plate (Figure 12, D).In addition, 
we observed an increase in lipid accumulation as vacuoles in the hepatocytes of the 
iron overloaded group (Figure 12, B). These vacuoles were not apparent in hepatic 
tissue from either control or deferasirox treated groups.  
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Figure 11. Average iron levels in mg/g tissue weight in hepatic tissue of gerbils in 
the experimental groups. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload 
followed by deferasirox treatment, 1m: 1 month interval, 3m: 3 months interval. (*) 
indicates significant difference from control, (†) indicates significant difference from iron 
overload group (P < 0.05).                           
 
 
 
 
-77- 
 
 
Figure 12. Iron deposition in hepatic tissue of Ctrl (A), IO (B,C), and IO+DFR(D)  
gerbils followed for 3 months. Ferric iron was detected by Prussian blue staining. (A) 
demonstrates no apparent iron deposition in the liver of control gerbils (200X). (B) 
depicts iron induced damage and lipid accumulation in hepatocytes as vacuoles (Arrow, 
400X). (C) shows iron accumulation in all areas of hepatic plate, but especially 
concentrated in the periportal region (200X). Large, intensely stained lobular masses 
represent macrophages. (D) demonstrates decreased iron deposition in all areas of 
deferasirox treated hepatic tissue (200X). Iron accumulation manifests as blue 
background staining at this magnification but is discernible as discrete deposits “dots” at 
higher power 
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Ferritin protein expression 
 We investigated whether the elevation in hepatic iron levels with iron overload is 
associated with an increase in hepatic ferritin protein expression using Western blot 
analysis. As expected, ferritin protein expression was 2.4 fold higher after ten weeks of 
iron overload. Ferritin levels decreased slowly over time, and it was 2.2 fold, and 2.1 
fold at one and three months follow up. Interestingly, one and three months of 
deferasirox treatment resulted in 23%, and 47.5% reduction in ferritin protein expression 
compared to that of the age matched iron overload value (Figure 13). 
 
Figure 13. Western blot analysis of ferritin heavy chain (ferH) protein expression 
in hepatic tissue of gerbils in the experimental groups. Effects of iron overload and 
deferasirox treatment on ferritin protein expression were analyzed. Results were 
obtained from six experiments and expressed as a percentage of the corresponding age 
matched control value (upper panel). Representative Western blot (lower panel). 1m: 1 
month interval, 3m: 3 months interval. (*) indicates significant difference from control, (†) 
indicates significant difference from iron overload group (P < 0.05) 
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Superoxide abundance 
   Liver specimens were evaluated for ·O2- generation within tissue sections 
utilizing HE fluorescence.  Iron overload induced a 167.0% increase in fluorescent 
staining in hepatic tissue three months after iron injections (P < 0.05). This increase was 
reduced by 48.6% with deferasirox treatment in hepatic tissue when compared to age- 
matched control (P < 0.05) (Figure 14). 
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Figure 14. Detection of hepatic superoxide by hydroethidine in Ctrl, IO, and 
IO+DFR. The increase in superoxide involves all regions of the hepatic plate (Upper 
panel). Quantification of hepatic superoxide as determined by intensity of 
fluorescent ethidium bromide-stained nuclei (Lower panel). 3m: 3 months interval. 
An asterisk (*) indicates significant difference from control animals, (†) indicates 
significant difference from iron overload (P < 0.05). 
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Protein oxidation 
 Iron catalyzed oxidation of proteins introduces carbonyl groups at lysine, 
arginine, proline, and threonine residues in a site specific manner. Protein modification 
by oxygen free radicals and other reactive species were analyzed in hepatic cells from 
control, iron overloaded, and deferasirox treated groups utilizing an OxyBlot™ detection 
kit. Interestingly, iron overload induced 1.6 fold increase in protein oxidation at 3 
months. Protein oxidation was reduced by 50.2% after three months of deferasirox 
treatment (P < 0.05) (Figure 15). 
 
 
Figure 15. Effect of iron overload or deferasirox treatment on hepatic protein 
carbonylation. (Left) Representative oxy-blots of hepatic protein isolates from Ctrl, IO, 
and IO+DFR.  (Right) Quantification of oxidatively modified proteins in hepatic protein 
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isolates obtained from the corresponding groups. 3m: 3 months interval. An asterisk (*) 
indicates significant difference from control animals, (†) indicates significant difference 
from iron overloaded animals (P < 0.05). 
 
Cell death  
To investigate whether iron overload induced alterations in oxidative stress are 
related to hepatic cell death, we examined the number of nuclei staining positively for 
DNA fragmentation by TUNEL assay. The apoptotic index in the hepatocytes of iron 
overloaded gerbils increased 7.5 fold compared to age-matched control  3 months post 
iron overload, while deferasirox treatment demonstrated a 41.0% reduction in the 
apoptotic index when compared to this iron overload induced increase (P < 0.05) 
(Figure 16). 
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Figure 16. Representative cross sections showing the changes in nuclei 
exhibiting DNA strand breakage as determined by TUNEL staining in Ctrl, IO, and 
IO +DFR. Bar = 50 µm (upper panel).  Quantification of hepatic apoptotic cells as 
determined by the number of TUNEL positive cells by the number of DAPI positive cells 
per mm2, apoptotic index, (Lower panel). 3m: 3 months interval. An asterisk (*) indicates 
significant difference from control animals, (†) indicates significant difference from iron 
overload (P < 0.05). 
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Bcl-2 apoptotic signaling 
The expression of the anti-apoptotic (Bcl-2) and the pro-apoptotic (Bax and Bad) 
proteins and the ratio of Bax to Bcl-2 were evaluated by western blotting. When Bax is 
in excess, Bcl-2 cannot bind and sequester all the Bax protein, thus allowing Bax to 
oligomerize and act on the mitochondrial membrane to cause release of cytochrome c 
from the inter-membrane space to the cytosolic space. Thus a higher Bax to Bcl-2 ratio 
would potentially increase the susceptibility to mitochondrial permeability. We 
investigated if there were any changes in the anti-apoptotic (Bcl-2) and pro-apoptotic 
(Bax and Bad) proteins in the experimental groups. The expression of Bax/Bcl-2 was 
62.1% higher than control after 10 weeks of iron loading (P < 0.05) (Figure 17). Bax/Bcl-
2 levels remained consistently elevated and were 52% and 121%  higher after 1- and 3-
months follow up compared to respective age matched controls (P < 0.05) (Figure 17). 
We demonstrated decreased levels of  Bax/Bcl-2 expression with deferasirox treatment 
and it was 21.7% and 47% lower after 1- and 3-months of treatment, respectively (P < 
0.05) (Figure 17). 
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Figure 17. Effects of iron overload and deferasirox treatment on Bax/Bcl-2 protein 
level in hepatic tissue of gerbils in the experimental groups. Results were obtained 
from six experiments and expressed as a percentage of the corresponding age matched 
control value (upper panel). Representative Western blot (lower panel). 1 m = 1 month 
interval, 3 m = 3 months interval.  (*) indicates significant difference from control, (†) 
indicates significant difference from iron overload group (P < 0.05). 
 
In addition, Bad expression was 73%, 52%, and 77% higher in the IO, 1 month-
IO and 3 months-IO, respectively (P < 0.05). With three months of deferasirox treatment 
Bad expression was reduced by 33% compared to age matched iron overload group (P 
< 0.05) (Figure 18).  
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Figure 18. Effects of iron overload and deferasirox treatment on Bad protein level 
in hepatic tissue of gerbils in the experimental groups. Results are obtained from 
six experiments in each group and expressed as a percentage of the corresponding age 
matched control value (upper panel). Representative Western blot (lower panel). 1 m = 
1 month interval, 3 m = 3 months interval.  (*) indicates significant difference from 
control, (†) indicates significant difference from iron overload group (P < 0.05). 
 
Caspase-3 activation 
One critical step in the execution of the apoptotic program that elicits DNA 
fragmentation is cleavage of caspase-3 into 19- and 17-kDa fragments. Caspases are 
cysteine dependent aspartate specific proteases which activate endonucleases integral 
in the final execution of nuclei and cell death. Cleaved caspase-3 is downstream of the 
Bcl-2 family apoptotic cascade and integrates apoptotic signaling from the cytokine/Fas 
and Ca2+/ER pathways as well. Caspase-3 activation, as measured by cleaved 
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caspase-3 fragment level, was markedly higher in the iron overload liver (86%, and 
102% after 1 and 3 month of follow up, respectively) as compared to age matched 
control liver (P < 0.05) (Figure 19). We demonstrated a significant reduction of cleaved 
caspase-3 by 21% in the 3 months deferasirox treatment group (P < 0.05) (Figure 9). 
No significant difference in the expression of the full length caspase-3 was observed 
between groups. 
 
 
Figure 19. Effects of iron overload and deferasirox treatment on full length and 
cleaved caspase-3 in hepatic tissue of gerbils in the experimental groups. Results 
were obtained from six experiments and expressed as a percentage of the 
corresponding age matched control value (upper panel). Representative Western blot 
(lower panel). 1 m = 1 month interval, 3 m = 3 months interval.  (*) indicates significant 
difference from control, (†) indicates significant difference from iron overload group (P < 
0.05). 
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Table 6. Regression analysis of the relationship between expression levels of 
specific proteins and TUNEL, HE staining intensity, liver weight, and hepatic iron 
levels obtained from experimental groups 
 
 Liver wt Iron Ferritin Oxyblot HE TUNEL 
Independent 
variables 
      
Liver wt N.T. 0.693† 0.703†† 0.513† 0.511† 0.562† 
Iron 0.693† N.T. 0.957††† 0.911††† 0.919††† 0.949††† 
Ferritin 0.703†† 0.957††† N.T. 0.922††† 0.935††† 0.927††† 
Oxyblot 0.513† 0.911††† 0.922††† N.T. 0.922††† 0.852†† 
HE 0.511† 0.919††† 0.935††† 0.922††† N.T. 0.869†† 
TUNEL 0.562† 0.949††† 0.927††† 0.852†† 0.869†† N.T. 
Apoptotic 
regulators 
      
Bax 0.427* 0.661† 0.696† 0.550† 0.535† 0.341* 
Bcl-2 0.135 0.299 0.321* 0.329* 0.272 0.111 
Bad 0.127 0.127 0.138 0.583† 0.575† 0.362* 
Caspase-3 
(cleaved) 
0.424* 0.637† 0.659† 0.846†† 0.824†† 0.689† 
(†††) indicates very high correlation, (††) indicates high correlation, (†) indicates moderate correlation, 
(*)indicates low correlation, N.T. = not tested. 
 
 
Discussion 
The iron overloaded gerbil, a well accepted animal model of iron overload, is 
thought to closely resemble many of the effects of iron overload seen in humans 
(Carthew, Dorman et al. 1993; Yang, Brittenham et al. 2003). Using the gerbil model of 
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iron overload, we have previously demonstrated that deferasirox treatment removes 
cardiac iron and reduces the iron associated increase in oxidative stress and ferritin 
expression (Al-Rousan, Paturi et al. 2009). Similar to our finding in the heart, here we 
demonstrate that iron overload caused hepatic iron deposition and lipid accumulation 
and resulted in a dramatic increase in hepatic iron content. This elevated level of iron 
deposition was also associated with increased ferritin protein expression, elevated 
levels of ROS, and cell death signals. Iron chelation by deferasirox reduced iron 
deposition and the induction of ferritin and Bax proteins, whose gene expression is 
thought to be linked to oxidative stress, suppressed iron overload-induced superoxide 
formation and protein oxidation, and reduced the incidence of hepatocyte death. These 
data collectively suggest that deferasirox may afford hepatic protection against iron-
induced pathogenesis. 
 
Deferasirox decreases hepatic iron and ferritin levels in the iron-overloaded gerbil 
We found that hepatic iron levels after three months of follow up were 
significantly lower than observed in the 10-week iron overload animals (P < 0.05). 
These observations are consistent with the findings by Wood et al. (Wood, Otto-Duessel 
et al. 2006) that body iron levels exhibit spontaneous (non chelator-mediated) 
redistribution and elimination. These levels, however, remained elevated and potentially 
harmful to hepatic tissue. Three months of deferasirox treatment significantly reduced 
hepatic iron content by 43.5% compared to that of the age-matched iron overloaded 
group (P < 0.05) (Figure 11). As expected from its predominantly biliary elimination 
clearance  (Hershko, Konijn et al. 2001), these iron removal data suggest that 
deferasirox appears to be particularly efficient for hepatocyte clearance. Similar to our 
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biochemical assessment, the findings from our histological data suggest that deferasirox 
is efficacious in removing liver iron. In addition, we also observed evidence of lipid 
accumulation in the iron-overloaded liver (Figure 12, B arrows). Elevated free iron has 
been shown to be hepatotoxic, possibly exerting its effects by interfering with 
mitochondrial or microsomal function which disrupts lipoprotein transport and fatty acids 
homeostasis (Baptista-Gonzalez, Chavez-Tapia et al. 2008; Duncan 2008; Raszeja-
Wyszomirska, Lawniczak et al. 2008). Interestingly, with deferasirox treatment we failed 
to find any evidence of fatty acid accumulation suggesting perhaps that this agent is 
efficacious in preventing iron-induced liver damage. More research to specifically 
address hepatic mitochondrial function in these groups will no doubt be useful in 
furthering our understanding the effect of deferasirox on liver physiology. 
It is well accepted that ferritin is the principal storage protein for iron (Arosio and 
Levi 2002). The increase in ferritin expression in response to iron overload is thought to 
provide a cytoprotective mechanism against iron induced toxicity (Balla, Jacob et al. 
1992; de Valk and Marx 1999). Nonetheless, it should be noted that although ferritin 
and hemosiderin have traditionally been regarded as ‘safe’ storage forms of iron, this 
does not mean that the iron contained in these molecules cannot potentiate the 
development of oxidative stress under certain conditions. Indeed, it has been recently 
demonstrated that the superoxide radical is capable of mobilizing iron from ferritin and 
that this can result in the production of iron-catalyzed hydroxyl radicals (Bartfay, 
Dawood et al. 1999).  
The synthesis of ferritin is tightly regulated and is dependent on intracellular iron 
levels. When iron is low, binding of the iron-regulatory proteins (IRP-1) to iron-
responsive elements (IRE) inhibits translation of ferritin. Conversely, when cellular iron 
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is high, the opposite regulation takes place (Ferrara and Taylor 2005). In the present 
study, we demonstrated a significant increase in ferritin levels with iron loading and 
more importantly, that these elevations were significantly suppressed with deferasirox 
treatment (Figure 13). These results are in agreement with previous findings that 
chelation therapy with deferoxamine reduced iron-induced ferritin upregulation in rat 
aorta (Ishizaka, Saito et al. 2005). To our knowledge, the present study is the first 
description of the effect of iron overload and deferasirox treatment on hepatic ferritin 
expression. 
It is thought that deferasirox does not chelate tightly bound iron stores (eg, 
hemoglobin or the cytochromes), but instead extracts iron from storage proteins such as 
ferritin with relatively weak bonds (Evens, Mehta et al. 2004). On the other hand, in vitro 
studies have shown that deferasirox is able to access the intracellular labile iron pool 
(LIP) (Glickstein, El et al. 2005; Glickstein, El et al. 2006). It is important to note here 
that ferritin-bound iron is in an equilibrium state with the free iron in the LIP (Crichton 
and Ward 2003).  Thus, it is plausible to postulate that deferasirox may indirectly reduce 
ferritin bound iron by shifting the equilibrium in favor of the more accessible iron in the 
LIP. 
 
Reduced hepatic iron levels are associated with decreases in tissue ROS  
Because humans have no physiologic means of eliminating excess iron, any 
persistent increase in intake may eventually result in iron overload. When the extent of 
iron accumulation exceeds the body's ability to safely sequester the surplus iron, free 
iron builds up in the LIP (Breuer, Epsztejn et al. 1996). Normally, the LIP represents 
only 3–5% of the total cellular iron (Arosio and Levi 2002). Iron overload can induce 
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about a three-fold increase in the iron level in hepatic LIP, which triggers oxidative 
stress and cell injury (Arosio and Levi 2002).   
The formation of highly toxic hydroxyl radical via Fenton and Haber-Weiss 
reactions, followed by the subsequent formation of lipid peroxidation products, is 
postulated to be an underlying mechanism of iron mediated liver injury (Britton and 
Bacon 1994; Staubli and Boelsterli 1998). In the liver, iron overload is thought to 
damage the hepatocytes and dysregulate a variety of metabolic pathways, which if 
allowed to proceed unchecked could eventually result in liver fibrosis, cirrhosis, or other 
liver diseases (Ramm and Ruddell 2005; Tsukada, Parsons et al. 2006). Iron chelators 
decrease the redox activity of iron through their ability to form complexes with Fe (III), 
preventing the reduction of Fe(III) by superoxide to the reactive Fe(II) state. 
  In the present study, we showed that ROS levels as superoxide anion (O2•– ) 
were increased in the iron-overloaded hepatic tissue as determined by hydroethidium 
staining (Figure 14). These findings are consistent with earlier data which have 
suggested that increased iron levels are associated with increases in liver ROS 
(Glickstein, El et al. 2006; Pardo Andreu, Inada et al. 2008). Possible sources of 
increased ROS with iron loading are not fully elucidated but could include the iron 
catalyzed Fenton-Haber Weiss reaction, redox cycling, and possibly iron associated 
changes in NADPH oxidoreductases and mitochondrial function (MacCarthy, Grieve et 
al. 2001; Galaris and Pantopoulos 2008; Kim, Kim et al. 2008; Pardo Andreu, Inada et 
al. 2008). Whether these changes in ROS are directly related to the improvements in 
histological appearance we observe with deferasirox treatment are not fully elucidated.  
Our data suggested that iron overload was associated with increased levels of 
protein oxidation in the liver (Figure 15) and importantly, that deferasirox treatment is 
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capable of decreasing the amount of oxidized proteins in the iron overloaded liver. 
Although the physiological effects of protein oxidation in the liver are not entirely 
elucidated, recent work has suggested that protein oxidation can alter hepatic enzyme 
activity. For example, the increased oxidative levels have been shown to alter the 
activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR), the rate 
limiting enzyme in the production of cholesterol (Pallottini, Martini et al. 2005). Whether 
the proteins identified in our analysis are related to hepatic metabolism is unknown and 
will necessitate further experimentation. Nonetheless, the decreases we see in the 
quantity of modified proteins and liver ROS levels are highly correlated with deferasirox-
associated improvements in liver iron levels and liver histology (Table 6). Taken 
together, these data suggest that deferasirox may be efficacious in preventing iron 
accumulation, ROS accumulation and iron-overload induced liver pathology.  
 
Reduced hepatic iron levels are associated with decreases in iron-associated cell death 
A link between oxidative stress and cell death has been reported in several 
conditions including hemochromatosis (Cooksey, Jouihan et al. 2004), alcoholic liver 
disease (Zima and Kalousova 2005), hepatitis, and liver cirrhosis (Kaplowitz 2000). 
However, the mechanism by which free radicals can induce cell death is not well 
understood. Here, we demonstrated that iron overload was associated with increased 
hepatic cell death as determined by increased incidence of TUNEL reactive nuclei 
(Figure 16). Interestingly, the number of TUNEL positive nuclei was significantly 
reduced with deferasirox treatment.  
To investigate the mechanism of iron overload-related DNA strand breakage that 
we observed in our TUNEL studies, we examined the expression of Bcl-2 family 
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proteins. It is thought that the ratio of Bax to Bcl-2 plays an important role in regulating 
the release of cytochrome-c from the mitochondria into the cytosol. This latter effect is 
favored as the balance shifts toward Bax leading to cell death (Oltvai, Milliman et al. 
1993). In iron overloaded animals, we found that Bax expression was elevated and that 
these levels were reduced with deferasirox treatment (Figure 17). To expand upon this 
finding we also examined the regulation of Bad, a pro-apoptotic member of the Bcl-2 
family that can displace Bax binding from Bcl-2 and Bcl-XL, resulting in cell death 
(Hengartner 2000). Similar to our findings with Bax, deferasirox treatment significantly 
decreased the expression of Bad (Figure 18). 
Caspase-3 is a key effector of mitochondrial-mediated apoptosis  (Cai, Yang et 
al. 1998; Porter and Janicke 1999; Goldspink 2003) that is normally activated by 
proteolytic cleavage (Cohen 1997). To investigate whether alterations in the regulation 
of caspase-3 may be involved, here we examined the expression of caspase-3 with iron 
overload and deferasirox treatment. With iron overload, we observed increases in the 
amount of cleaved caspase-3 (Figure 19). Further, we demonstrated that deferasirox 
administration decreased caspase-3 cleavage. These data, in conjunction with our 
findings that deferasirox alters the regulation of Bcl-2, Bax and Bad, suggest that 
deferasirox may decrease iron-induced apoptosis by affecting the regulation of the 
mitochondrial apoptotic cascade. This is in agreement with the results of other recent 
investigations that have implicated increased iron levels as causing mitochondrial 
dysfunction and apoptosis (Eaton and Qian 2002; Walter, Knutson et al. 2002). Whether 
the activation of the mitochondrial apoptotic pathway is dependent upon iron-associated 
increases in ROS per se, or ROS acting in concert with other factors, is worthy of 
detailed studies. 
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Conclusions 
In conclusion, our data suggest that iron overload is associated with increases in 
hepatic iron levels, indices of ROS, and increased hepatic apoptosis and that 
deferasirox is efficacious in attenuating these parameters. Given that iron overload is 
associated with an increased risk of developing liver fibrosis, decreased hepatic 
function, and hepatic cancer (Bonkovsky and Lambrecht 2000; Fattovich, Stroffolini et 
al. 2004) it is likely that deferasirox treatment may find a use for the treatment and / or 
prevention of several hepatic disorders.  
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Article #3: Corresponds to Specific Aim #3 
To determine the long term cardiovascular complications associated with iron 
overload and to determine if chronic deferasirox administration is able to 
prevent/reduce these complications, including those related to cardiac 
remodeling and functional abnormalities. 
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Abstract 
Iron-induced cardiovascular disease is the leading cause of death in iron-
overload patients.  Deferasirox is a novel tridentate oral chelator that exhibits a half-life 
suitable for once-daily dosing; however, little is known regarding the effectiveness of 
this agent in preventing iron-induced cardiovascular dysfunction. Adult male Mongolian 
Gerbils were randomly divided into three groups: control, iron overload, and iron 
overload followed by deferasirox treatment. Iron overload animals received iron-dextran 
100 mg/kg i.p /5 d for 10 wks while deferasirox was given 100 mg/kg/d p.o for 9 months 
post iron loading. Cardiac and aortic iron levels were determined by inductively coupled 
plasma atomic emission spectrometry.  Gerbil EKG (standard leads I, II, & III) and 
echocardiograms (Philips Sonos 5500) were obtained in anesthetized animals at regular 
intervals. Compared to control animals, iron concentration was 3.3 and 2.4 fold higher in 
iron overloaded heart and aorta respectively (P < 0.05). Deferasirox treatment reduced 
cardiac and aortic iron levels by 31.6%, and 34.6%, respectively (P < 0.05). These 
results were consistent with the decrease in cellular iron deposition observed with 
Prussian blue iron staining. Cardiac mass/body wt ratio was increased by 34% in the 
iron overloaded group and was 24% lower with deferasirox treatment. Iron overloaded 
gerbils were found to exhibit frequent arrhythmias including premature ventricular 
tachycardia (6/10), supraventricular tachycardia (3/10), recurrent ventricular tachycardia 
(4/10), and increased mortality (3/10) with the latter occurring most likely due to fatal 
arrhythmias. Echocardiographic assessment demonstrated iron-induced increases in 
LVPWd, LVIDd, and LVSd by 48.6%, 26.2%, and 42.4%, respectively (P < 0.05). 
Similarly, ejection fraction and fractional shortening were reduced by 29.6% and 22.9% 
compared to controls (P < 0.05). Deferasirox reduced the incidence of iron-induced 
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arrhythmia and either prevented or significantly decreased iron-induced changes in 
cardiac structure (LVIDd: 23.6%; P < 0.05), LVPWd (21.5%; P < 0.05), LVSd (27.2%; P 
< 0.05) and function (EF: 29.8%; P < 0.05), (FS: 27.8%; P < 0.05). Taken together, 
these data suggest that once daily oral deferasirox treatment appears to be effective in 
preventing or reducing iron-induced cardiovascular abnormalities. 
Introduction 
 
Despite dramatic improvements in care, iron induced cardiac disease remains 
the most frequent cause of death in thalassemia major and a major life-limiting 
complication of other transfusion-dependent patients, hereditary hemochromatosis, and 
other forms of iron overload (Neufeld 2006). The most common form of cardiac 
hemosiderotic injury is dilated cardiomyopathy, generally manifesting as systolic or 
diastolic dysfunction (Liu and Olivieri 1994). Signs of myocardial damage due to iron 
overload include arrhythmia, angina, cardiomegaly, heart failure, and pericarditis. Iron 
overload can also produce conduction defects secondary to iron deposition in the 
Bundle of His and the Purkinje system (Schwartz, Li et al. 2002). Sudden death due to 
arrhythmia can therefore occur among patients with advanced iron overload (Klintschar 
and Stiller 2004). Although prophylactic therapy with angiotensin converting enzyme 
inhibitors and β-blockers can help reduce cardiac morbidity and mortality (Trad, 
Hamdan et al. 2009), the mainstay of therapy for cardiac iron overload remains iron 
chelating agents. The goal of chelation therapy is primarily the prevention of iron 
overload in order to preserve organ function and improve patient survivability. To date, 
only deferoxamine is globally available for the first-line treatment of transfusion-related 
iron overload. Effective chelation with deferoxamine has been shown to increase 
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survival rate and prolong length and quality of life for transfusion patients (Obejero-Paz, 
Yang et al. 2003). However, deferoxamine chelation therapy is associated with a 
cumbersome treatment regimen and toxic side effects resulting in low patient 
adherence. In addition, treatment with deferoxamine has limited clinical outcomes and 
some patients still die of iron-induced cardiac disease despite apparently adequate liver 
iron chelation.  
Unlike deferoxamine, deferasirox is an orally effective once daily iron chelating 
agent with favorable patient satisfaction (Neufeld 2006; Cappellini and Pattoneri 2009).  
Deferasirox was recently approved by the Food and Drug Administration (FDA) and is 
the first oral medication approved in the United States for this purpose (Lindsey and 
Olin 2007; Stumpf 2007). As deferasirox is well tolerated, it is expected to greatly 
enhance the acceptance of iron chelation therapy and offer a new alternative to 
burdensome continuous infusion therapy (Stumpf 2007). Whether deferasirox is 
efficacious in preventing the cardiovascular complications associated with iron overload 
is not yet clear. To address this gap in our understanding, we examined if the chronic 
administration of deferasirox is capable of removing excess iron from heart and other 
tissues, and whether it is capable of preventing or reducing the severity of iron-induced 
cardiac complications in the iron overloaded gerbil, a well accepted animal model of iron 
overload that is thought to closely resemble the effects of iron overload seen in humans 
(Carthew, Dorman et al. 1993).  Our data suggest that once daily oral deferasirox 
treatment appears to be effective in preventing or reducing iron-induced cardiovascular 
abnormalities. 
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Results 
Characterization of animals 
Total body and heart weights were obtained and compared. All animals tolerated 
the iron loading and chelation without any apparent ill effects. The body weights of iron 
overloaded gerbils were similar to controls, indicating that the injection of iron dextran 
did not result in debilitation or weight loss. Cardiac, hepatic and kidney weights were 
increased 34%, 41.4% and 30.9% (P < 0.05), respectively, in the iron overloaded group, 
and deferasirox treatment was effective in reducing iron-associated increases in whole 
tissue weight by 23.9%, 16.3%, 23.7% (Table 7). 
 
Table 7. Average heart, liver, and Kidney weights of gerbils in the experimental 
groups followed for 9 months 
Group 
n = 10/ group Heart/body wt (%)  Liver/body wt (%)  Kidney/body wt (%) 
Ctrl 0.39 ± 0.01 4.1 ± 0.31 0.81 ± 0.02 
IO 0.52 ± 0.02* 5.8 ± 0.30* 1.05 ± 0.03* 
IO + DFR 0.40 ± 0.01† 4.9 ± 0.34† 0.8 ± 0.02† 
    An asterisk (*) or cross (+) indicates significant difference  from age matched control and  iron overloaded 
groups, respectively. 
 
Cardiac, aortic, and hepatic iron levels 
Compared to hearts obtained from control animals, iron concentration was 3.3 
fold higher in iron overloaded hearts (P < 0.05). Deferasirox treatment for 9 months 
resulted in a 31.6% decrease in cardiac iron level (P < 0.05) (Figure 20, A). Aortic iron 
concentration was 2.4 fold higher in the iron overloaded group compared to controls (P 
< 0.05). Nine months of deferasirox treatment decreased aortic iron level by 34.6% (P < 
0.05) (Figure 20, B). Similarly, hepatic iron concentration was 49.5 fold higher than that 
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of control after nine months of follow up after iron overload. Hepatic iron concentration 
was 47.4% lower after 9 months of deferasirox treatment compared to that observed in 
the untreated iron overloaded animals. Prussian Blue iron staining of the left ventricle 
from the iron overloaded group indicates an increase in iron deposition and tissue 
damage compared to that of control. In sections of the left ventricular sections obtained 
from deferasirox treated animals, a lower iron deposition and preservation of tissue 
morphology was observed (Figure 21). 
 
 
 
Figure 20. Average iron levels in mg/g tissue weight in cardiac (A), aortic (B), and 
hepatic (C) tissue of gerbils in the experimental groups followed for 9 months. 
Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload followed by deferasirox 
treatment. (*) indicates significant difference from control, (†) indicates significant 
difference from iron overload group. 
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Figure 21. Histological analysis of cardiac tissue of Ctrl (A), IO (B), and IO+DFR 
(C) gerbils followed for 9 months. Ferric iron was detected by Prussian blue staining. 
No apparent iron deposition was observed in control gerbils. Iron overload resulted in 
morphological alteration and iron accumulation in the interstitium and in cardiac 
myocytes. Deferasirox treatment preserved tissue morphology and diminished iron 
deposition. Bar represents 100 µm; images were taken at 400X original magnification. 
 
Electrocardiographic evaluation 
Electrocardiographic measurements suggested an increased incidence of 
arrhythmias with iron overload (Figure 22). Iron overloaded gerbils were found to exhibit 
frequent premature ventricular tachycardia, (PVC) (6/10), supraventricular tachycardia, 
(SVT) (3/10), recurrent sustained and non sustained ventricular tachycardia, (VT) 
(4/10), and increased incidence of death (3/10) with the latter occurring most likely due 
to fatal arrhythmias (Figure 23). In addition, we observed an increased incidence of 
bundle branch block, (BBB) (6/10), negative P wave (8/10), and T wave flattening (5/10) 
(Figure 23).  
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Figure 22. Representative ECGs (standard leads I, II, III) from control, iron 
overload, and deferasirox (DFR) treated groups followed for 9 months. EKG trace 
from iron overloaded animal (middle) exhibits ventricular tachycardia, EKG trace from 
control (left) and deferasirox treated animal (right) exhibit normal rhythm. 
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Figure 23. Frequency of electrocardiographic abnormalities observed in Ctrl, IO, 
and IO+ DFR followed for 9 months. PVC = premature ventricular tachycardia, SVT = 
supraventricular tachycardia, VT = ventricular tachycardia, BBB = bundle branch block, 
p = p wave, T = T wave. 
 
Echocardiographic evaluation (cardiac structure) 
Alterations in cardiac structure were evaluated by echocardiographic 
measurements. Our data demonstrated that LVPWd increased by 39.1% and 48.6% in 
the iron overloaded group after 6 and 9 months of follow up, respectively (P < 0.05) 
(Figure 24). LVPWd was 21.4% and 21.5% lower after 6, and 9 months of follow up, 
respectively, with deferasirox treatment (P < 0.05) (Figures 24, 25). Similarly, LVIDd 
increased by 18.5%, and 26.2% in the iron overloaded animals after 6, and 9 months of 
follow up, respectively (P < 0.05) (Figure 24). In the deferasirox treatment group, LVIDd 
was 16.5% and 23.6% lower after 6 and 9 months of follow up, respectively than that 
observed with iron overload (P < 0.05). In addition, LVSd was 31.5% and 42.4% higher 
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in the iron overloaded group after 6 and 9 months of follow up, respectively compared to 
control (P < 0.05). These levels were lower by 23.4% and 27.2% with 6 and 9 months of 
deferasirox treatment, respectively (P < 0.05) (Figure 24).  
Alterations in cardiac structure were evaluated by echocardiographic 
measurements. Our data demonstrated that LVPWd was increased by 39.1% and 
48.6% in the iron overloaded group after 6 and 9 months of follow up, respectively (P< 
0.05) (Figure 24). LVPWd was 21.4% and 21.5% lower after 6, and 9 months of follow 
up, respectively, with deferasirox treatment (P < 0.05) (Figures 24, 25). Similarly, LVSd 
was 31.5% and 42.4% higher in the iron overloaded group after 6 and 9 months of 
follow up, respectively compared to control (P < 0.05). These levels were lower by 
23.4% and 27.2% with 6 and 9 months of deferasirox treatment, respectively (P < 0.05) 
(Figure 24).  
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Figure 24. Effect of iron overload and deferasirox treatment on left ventricular 
dimension. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload followed by 
deferasirox treatment. BL = baseline (before iron loading), mo = months of follow up. 
LVPWd = left ventricular posterior wall dimension during diastole, LVIDd = left 
ventricular internal wall dimension during diastole, LVSd =  left ventricular septal 
dimension during diastole 
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Figure 25. Representative M-mode echocardiograms from Ctrl (A), IO (B), and IO+ 
DFR (C) groups followed for 9 months. Arrows indicate left ventricular posterior wall 
dimension (LVPW) and is 0.127 cm, 0.153 cm, and 0.136 cm in A, B, and C 
respectively. 
 
Echocardiographic evaluation (cardiac function) 
Cardiac systolic and diastolic function was evaluated by echocardiographic 
measurements. Compared to control, ejection fraction was reduced by 22%, and 29.6% 
in the iron overloaded group after 6, and 9 months of follow up, respectively (P < 0.05) 
(Figure 26). Similarly, fractional shortening was 12.9% and 29.9% lower than control 
after 6, and 9 months of follow up, respectively (P < 0.05) (Figure 26). 
Iron-induced decreases in ejection fraction were 17.7% and 29.8% higher than 
iron overload group after 6 and 9 months of deferasirox treatment, respectively (P < 
0.05) (Figure 26). Likewise, iron induced alteration in fractional shortening were 10% 
and 27.8% higher than iron overload group after 6 and 9 months of deferasirox 
treatment (P < 0.05) (Figure 26). In addition, gerbils in the iron overloaded group 
exhibited a higher frequency of regurgitation of all three cardiac valves (mitral 6/10, 
tricuspid 6/10, and aortic 3/10) (Figure 27).  
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Figure 26. Effect of iron overload and deferasirox treatment on left ventricular 
ejection fraction (EF), and fractional shortening (FS) in gerbils from experimental 
groups. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload followed by deferasirox 
treatment. BL = baseline (before iron loading), mo = months of follow up.  
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Figure 27. Frequency of cardiac valvular regurgitations observed in Ctrl, IO, 
IO+ DFR followed for 9 months. MR = mitral valve regurgitation, TR = tricuspid 
valve regurgitation, AR = Aortic valve regurgitation. 
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Figure 28. Correlation between cardiac iron concentration and heart/body wt, or 
echocardiographic parameters. LVPWd = left ventricular posterior wall dimension 
during diastole, LVIDd = left ventricular internal wall dimension during diastole, LVSd =  
left ventricular septal dimension during diastole, EF = ejection fraction, FS = fractional 
shortening. R = correlation coefficient. 
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Discussion 
Here, we examine the efficacy of chronic deferasirox administration in preventing 
iron induced cardiac complications in the gerbil model of iron overload. Our data are 
consistent with the notion that deferasirox treatment removes cardiac iron and reduces 
cardiac damage, remodeling, arrhythmias, and declines in indices of cardiac function 
that are typically associated with iron overload. 
Deferasirox removes cardiac, aortic, and hepatic iron  
  Iron distribution in the hearts of iron overloaded gerbils is thought to be similar to 
that reported in iron overloaded human hearts (Carthew, Dorman et al. 1993). Our 
findings demonstrated that cardiac and aortic iron concentrations nine months post iron 
loading were 3.3- and 2.4- fold higher than that of control. Hepatic iron levels were 
strikingly higher than that of heart and aorta and were 49.5 fold higher than that of 
corresponding control. Chronic deferasirox administration significantly reduced iron 
concentrations from these tissues and were 31.6%, 34.6%, and 47.4% lower than iron 
overload group in heart, aorta, and liver, respectively (Figures 20, 21). These results are 
consistent with previous studies suggesting that deferasirox is effective in cardiac and 
hepatic iron removal (Wood, Otto-Duessel et al. 2006; Otto-Duessel, Brewer et al. 
2008). Whether the disparity in iron levels that we see among tissues is related to 
relative differences in the rate or the mechanism of iron uptake or clearance is not clear. 
It has been previously suggested that the liver has especially high efficiency of iron 
clearance that is related to membrane potential (de Silva, Askwith et al. 1996). In 
addition, it is thought that the rate of iron clearance from the myocardium is six times 
slower than that of liver (Oudit, Sun et al. 2004). Nonetheless, as similar findings have 
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been observed with deferoxamine treatment (Anderson, Westwood et al. 2004), it is 
less likely that these differences are chelator-dependent. Specific mechanisms remain 
to be established. 
Deferasirox treatment preserves cardiac structure and prevents ventricular remodeling 
Iron induced cardiac hypertrophy and ventricular remodeling is a serious long 
term complication associated with iron overload (Hahalis, Alexopoulos et al. 2005). 
Previous findings have suggested that chelation therapy with deferoxamine helps 
prevent iron induced cardiac hypertrophy and failure in the clinic (Pennell, Sutcharitchan 
et al. 2008) and in animal studies (Yang, Brittenham et al. 2003).  Whether deferasirox 
produces a similar effect is not clear. Our findings suggest that iron overload was 
associated with increased cardiac mass, and a progressive increase in left ventricular 
wall dimensions, which reached significance at six- and nine- months following iron 
loading. With chronic deferasirox treatment, both cardiac mass and left ventricular 
dimensions tended to be preserved with values similar to that found in the control 
animals (Table 7, Figure 24). This is in agreement with recent case reports that have 
demonstrated that deferasirox treatment restored cardiac left ventricular diameter, left 
ventricular septum thickness, and left ventricular posterior wall dimension (Kiguchi, Ito 
et al. 2009) and reversed dilated cardiomyopathy (Kiguchi, Ito et al. 2009; Trad, 
Hamdan et al. 2009) in  patients with iron overload. The mechanism by which chelation 
therapy with deferasirox confers such cardioprotection is not known. We have 
previously demonstrated that deferasirox treatment reduced iron induced oxidative 
stress and MAPK phosphorylation (Al-Rousan, Paturi et al. 2009), both of which are 
thought to be implicated in cardiac hypertrophy. Nevertheless, a causal link between 
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oxidative stress, MAPK phosphorylation, and cardiac remodeling, along with the effect 
that we see with deferasirox treatment, cannot be established from the current evidence 
and will necessitate further experimentation.  
Deferasirox treatment preserves cardiac function and reduces incidence of arrhythmia 
  Without adequate control of iron overload, ongoing cardiac iron accumulation 
results in iron deposition in cardiac myocytes and the conduction system, which is 
thought to predispose the heart to recurrent arrhythmias and heart failure (Klintschar 
and Stiller 2004; Demant, Schmiedel et al. 2007). The mechanism of iron induced 
cardiac arrhythmias is not entirely elucidated, but it has been suggested that labile “free” 
iron can directly interact and interfere with a variety of ion channels within 
cardiomyocytes including L-type calcium channel, the ryonidine sensitive calcium 
channel, voltage gated sodium channel, and delayed rectifier potassium channel (Oudit, 
Sun et al. 2003; Wood, Enriquez et al. 2005; Oudit, Trivieri et al. 2006). Similar to 
findings from previous studies, we demonstrate that iron overload was associated with 
increased incidence of arrhythmias including premature ventricular contractions, 
supraventricular- and ventricular tachycardia, and frequent bundle branch blocks (Yang, 
Dong et al. 2002; Laurita, Chuck et al. 2003). As predicted, chronic deferasirox 
treatment was associated with lower incidence of EKG changes, and no evidence of 
ventricular tachycardia was observed in treated animals (Figure 23). This is consistent 
with previous findings that suggested that deferoxamine treatment prevents EKG 
abnormalities in the iron overloaded gerbil (Obejero-Paz, Yang et al. 2003).  How 
chelation therapy may produce these effects is not clear. It is thought that iron 
accumulation in the bundle of His and Purkinje fibers results in delay or blockage of 
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myocardial electrical conduction (Schwartz, Li et al. 2002). Thus, it is likely that 
chelating agents, by removing iron accumulated in the conduction system, may improve 
electrical conduction and thus reduce the incidence of EKG abnormalities associated 
with iron overload. Future experiments designed to directly test this possibility will no 
doubt be useful in increasing our understanding of how deferasirox exerts its effects. 
Iron overload was also associated with progressive decline in left ventricular 
ejection fraction and fractional shortening accompanied with an increase in the 
frequency of cardiac valve regurgitation. Deferasirox treatment tended to preserve 
cardiac function and only a slight decline in ejection fraction was observed (Figure 26). 
Similar findings have been demonstrated by Kiguchi and collegues (Kiguchi, Ito et al. 
2009) where deferasirox treatment restored ejection fraction and cardiac functions in a 
patient with cardiac iron overload. Whether the abnormalities in cardiac structure and 
function we observed are directly related to iron induced toxicity is unknown and will 
necessitate further experimentation. Nonetheless, the changes that we see in heart 
mass, left ventricular dimension, ejection fraction, and fractional shortening are highly 
correlated with cardiac iron concentration (Figures 27, 28).  Taken together, these data 
suggest that deferasirox may be efficacious in the treatment and / or prevention of iron-
overload induced cardiac complications.  
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IRON LEVELS IN OTHER TISSUES 
 
 
Pancreatic iron level 
We examined the effect of deferasirox treatment at one and three months on 
pancreatic iron concentration in the Mongolian gerbil. Compared to control, iron 
concentration was significantly higher in the overloaded animals. Our results 
demonstrated 37.9% reduction in pancreatic iron after three months of deferasirox 
treatment compared to age matched-untreated group (P < 0.05) (Figure 29). Similar 
results have been observed with Prussian Blue iron staining were iron deposition was 
increased in the pancreatic tissue of the iron overloaded animals especially in the 
parenchyma. Tissue sections from animals treated with deferasirox for three months 
exhibited an observable clearance of iron deposits and no apparent iron deposition was 
observed in control tissues (Figure 30). 
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Figure 29. Average iron levels in mg/g tissue weight in pancreatic tissue of 
gerbils in the experimental groups. Ctrl: control, IO: Iron overload, IO+ DFR: Iron 
overload followed by deferasirox treatment, 1 m: 1 month interval, 3 m: 3 months 
interval. (*) indicates significant difference from control, (†) indicates significant 
difference from iron overload group (P < 0.05).   
 
 
 
 
 
Figure 30. Histological analysis of pancreatic tissue of control, iron overload, and 
deferasirox treated groups followed for 3 months. Ferric iron was detected by 
Prussian blue staining. No apparent iron deposition was observed in control gerbils. Iron 
overload resulted in iron accumulation in parenchymal cells and to a lesser extent in 
pancreatic β-cells. Deferasirox treatment diminished iron deposition from all regions of 
pancreatic tissue. Images were taken at 400X original magnification. 
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Kidney iron level 
Kidney samples from animals in the experimental groups have been examined 
for iron level using ICP-AES technique. Compared to that of the corresponding age 
matched control group iron concentration in the iron overloaded groups were 97-, 51-, 
and 57- fold higher in IO, 1 month-IO, and 3 months-IO, respectively, (P < 0.05) (Figure 
31). No significant reduction in kidney iron levels were observed after 1, or 3 months of 
deferasirox treatment. 
 
Figure 31. Average iron levels in mg/g tissue weight in kidney tissue of gerbils in 
the experimental groups. Ctrl: control, IO: Iron overload, IO+ DFR: Iron overload 
followed by deferasirox treatment, 1 m: 1 month interval, 3 m: 3 months interval. (*) 
indicates significant difference from control. (P < 0.05)  
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CHAPTER V 
GENERAL DISCUSSION 
 
The primary purpose of the present study was to investigate the effect of 
deferasirox treatment on iron overload-related complications with special emphasis on 
the heart. To address this purpose, iron overload associated alterations in cardiac and 
hepatic mass, iron content, histology, oxidative stress, protein expression, and cardiac 
structure and function were assessed in iron overloaded or deferasirox treated gerbils in 
comparison to control. 
More than a decade ago, Carthew and his colleagues (Carthew, Dorman et al. 
1993) introduced the Mongolian gerbil model of iron overload. It duplicated, for the first 
time, the structural cardiomyopathy and hepatic dysfunction found clinically in patients 
with chronic iron excess. In a series of studies by others (Schwartz, Li et al. 2002; Yang, 
Dong et al. 2002) and in our own laboratory (Walker, Epling et al. 2007), the gerbil has 
been found to provide an animal model that reproduces many of the essential functional 
and structural features of iron-induced liver and heart disease in patients. Tissue iron 
levels, however, vary among studies based on the dosing regimen of iron-dextran 
administration (Kaiser, Davis et al. 2004). Cardiac and hepatic iron levels measured in 
the present study fall within the range of iron levels detailed in other studies that have 
used a similar dosing regimen (Wood, Otto-Duessel et al. 2006; Otto-Duessel, Aguilar 
et al. 2007). Iron chelation with deferasirox was given at 100mg/kg/day. This dose was 
chosen based on an earlier study evaluating the dose-response of deferasirox in the 
gerbil model (Wood at al. 2004). The highest dose, 100 mg/kg daily, was shown to 
significantly reduce hepatic iron content, while lower doses were not effective. Gerbils 
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have a 7.8-fold higher surface area to mass ratio, and corresponding metabolic rate, 
than humans. The gerbil deferasirox dose of 100 mg/kg translates to only two-thirds of 
the standard human dose (20 mg/kg) when normalized according to body surface area 
(Otto-Duessel, Aguilar et al. 2007); this is appropriate given that there is not ongoing 
transfusional iron accumulation.  
 
Effect of iron overload and deferasirox treatment on tissue iron concentration  
Results from previous studies and from the present investigation indicate that 
iron accumulates primarily in the liver and to lower extent in the heart and other tissues. 
For example, hepatic iron concentration measured in the present study was 
approximately 58 fold higher whereas cardiac iron concentration was only 7.4 fold 
higher than age matched control animals after 3 months of follow up. On the other hand, 
deferasirox treatment for three months resulted in 43.5% reduction in hepatic iron 
whereas cardiac iron was reduced by only 23.5%. It is thought that the mechanisms of 
iron uptake and clearance differ in heart and liver tissue, resulting in differing iron 
transport kinetics (Schwartz, Li et al. 2002). Previous studies have suggested that 
cardiac iron is cleared six-times more slowly than liver iron (Oudit, Sun et al. 2004). 
Although not directly examined, this phenomenon may explain why many iron overload 
patients develop cardiac dysfunction even though their liver iron levels appear to be 
only slightly elevated. As such, there is a need for more research to determine how 
elevated liver iron concentrations may correspond to elevations in cardiac iron levels 
and an increased risk of possibility of cardiac damage.  
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Effect of iron overload and deferasirox treatment on tissue iron distribution 
It has been suggested that tissue iron deposition occurs in a non-homogenous 
fashion. Similar to previous studies, histological examination of cardiac sections from 
iron overloaded gerbils demonstrated that excess iron accumulates primarily in the 
cardiomyocytes, cardiac macrophages, and in interstitial spaces of the heart. In patients 
with iron overload, it has been reported that iron deposition tends to be more extensive 
in the epicardial third of the ventricle, followed by the subendocardium and papillary 
muscle, and least in the middle third of the ventricular wall (Walker, Black et al. 2004). 
Iron accumulations in the cardiac conduction system, coronary arteries, and valves are 
usually limited, but involvement of the conduction system is associated with cardiac 
arrhythmias. In the liver, iron deposition tends to be more localized to the periportal 
region as opposed to the centrilobular region. Given the high oxygen concentration and 
mitochondrial volume in the periportal zone, it has been suggested that iron can be 
especially toxic to this particular region of the hepatic plate. Indeed, periportal necrosis 
has been described in both humans (Deugnier, Loreal et al. 1992; Hubscher 2003) and 
experimental animals (Whittaker, Hines et al. 1996) suffering from hepatic toxicity due to 
iron overload. Histological examination of cardiac and hepatic tissue sections from 
deferasirox treated gerbils suggest that deferasirox removes iron from cardiomyocytes 
and hepatocytes, and perhaps from macrophages, albeit at a much lower rate.  
 
Effect of iron overload and deferasirox treatment on ferritin protein expression 
  Changes in tissue iron concentration were paralleled by changes in ferritin 
protein expression. We demonstrated that ferritin heavy chain levels were 1.6 fold and 
2.1 fold higher than control in the iron overloaded heart and liver, respectively, after 
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three months of follow up. Similar to our observation with tissue iron clearance, 
deferasirox treatment reduced cardiac and hepatic ferritin by 38% and 47.5%, 
respectively. The effect of iron chelation therapy on serum ferritin expression is well 
documented in the literature as serum ferritin is a common diagnostic tool of body iron 
(Perifanis, Christoforidis et al. 2007; Walter, Macklin et al. 2008). However, there is a 
limited body of evidence on the effect of iron overload or chelation therapy on ferritin 
expression in intact tissue. Only one study has addressed the effect of iron overload on 
cellular ferritin expression in vitro (Tran, Eubanks et al. 1997) while one other study 
demonstrated that chelation therapy with deferoxamine is associated with reduced iron-
induced ferritin upregulation in rat aorta (Ishizaka, Saito et al. 2005). To our knowledge, 
the present study is the first description of the effect of iron overload and deferasirox 
treatment on cardiac and hepatic ferritin expression. 
It is thought that the increase in ferritin expression in response to iron overload 
provides a cytoprotective mechanism against iron induced toxicity (de Valk and Marx 
1999). Nonetheless, it should be noted that although ferritin and hemosiderin have 
traditionally been regarded as ‘safe’ storage forms of iron, this does not mean that the 
iron contained in these molecules cannot potentiate the development of oxidative stress 
under certain conditions. Indeed, it has been recently demonstrated that the superoxide 
radical is capable of mobilizing iron from ferritin and that this can result in the production 
of iron-catalyzed hydroxyl radicals (Bartfay, Dawood et al. 1999).  
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Effect of iron overload and deferasirox treatment on oxidative stress indices and 
apoptosis 
While no single mechanism is likely to account for the complex pathophysiology 
of iron-induced organ damage, it is believed that iron mediated formation of harmful free 
radicals  plays a major role (Kell 2009). Indeed, several different investigations have 
reported an increase in ROS generation in response to iron overload. For example, 
previous studies have demonstrated an increase in aldehyde-derived peroxidation 
products in both murine (Bartfay, Dawood et al. 1999), and gerbil models (Otto-Duessel, 
Aguilar et al. 2007) of iron overload. In addition, using an oxidative fluorescent dye, Day 
and collegues (Day, Duquaine et al. 2003) have suggested an increase in aortic 
oxidative stress in the iron overloaded mouse. Here, we demonstrated that iron 
overload was associated with an increase in superoxide generation and protein 
oxidation in heart and liver. It is thought that metal catalyzed oxidation of proteins 
introduces carbonyl groups (aldehydes and ketones) at lysine, arginine, proline or 
threonine residues in a site-specific manner (Stadtman 1993). This oxidative 
modification can modulate essential biochemical characteristics of proteins such as 
enzymatic activity (Oliver, 1987), the DNA binding activity of transcription factors 
(Pognonec, Kato et al. 1992), or the susceptibility of proteins to proteolytic degradation 
(Wolff and Dean 1986).  Although similar findings of reduced ROS with deferasirox have 
been found in vitro using cardiac myocytes (Glickstein, El et al. 2006), to our knowledge 
this is the first report to demonstrate that deferasirox is capable of reducing ROS in the 
intact tissue. 
In the present study, the origin of iron-induced increases in superoxide anion was 
not investigated. Previous studies have shown that the mitochondria play a primary role 
 
 
-124- 
 
within the cell both in the handling of iron and in energy production by oxidative 
phosphorylation process. Indeed, it is well accepted that mitochondria represent a 
primary target of oxidative injury, and thus are the main source for ROS. It has been 
shown that ROS are produced through the respiratory chain at a rate which is 
dependent on the metabolic state of the mitochondria (Pietrangelo, Montosi et al. 2002). 
In the presence of iron ions, ROS give rise to highly-reactive oxidizing species like the 
hydroxyl radical (HO•) (Burkitt and Mason 1991; Nunoshiba, Obata et al. 1999). This 
increase in oxidizing species in turn may destabilize one or more components of the 
electron transport chain that could lead to further ROS accumulation (Bacon, O'Neill et 
al. 1993). Experiments designed to assess mitochondrial function with iron overload and 
the effects of deferasirox on mitochondrial function will no doubt be useful in examining 
this possibility. 
How increased iron (or ROS) levels may negatively influence the structure and 
function of target tissue is not well understood but recent data suggests that excessive 
iron and iron mediated ROS elicit a wide spectrum of responses. These responses 
depend upon the severity of the damage, which is further influenced by the cell type, the 
magnitude of the dose, and the duration of the exposure. Nonetheless, there are 
controversial reports regarding the ultimate physiological outcome of these triggered 
responses, ranging from cell survival and adaptation (hypertrophy) to cell death 
(apoptosis) (Martindale and Holbrook 2002). In the present investigation, we 
demonstrated that iron overload was associated with increased phosphorylation of the 
three subfamilies of MAPK: ERK1/2, p38, and JNK. Interestingly, the maximum 
phosphorylation signal for p38 and JNK was higher than that observed for ERK1/2. This 
result could be justified in the context of p38-MAPK and JNKs being the two principal 
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MAPK subfamilies mediating cellular stress signals, whereas the ERKs are primarily 
associated with cell growth and proliferation. These results are in agreement with 
previous work that suggested increased MAPK phosphorylation associated with ROS 
alone (Bhat and Zhang 1999; Park, Yoo et al. 2005)  or ROS together with iron overload 
(Dai, Huang et al. 2004). In the present report we show that deferasirox treatment 
diminishes the extent of iron overload-dependent MAPK phosphorylation. Whether the 
induction of MAPK phosphorylation is dependent upon iron excess, ROS,  or these 
acting in concert with other factors is worthy of detailed studies. 
It is thought that the magnitude of ROS plays a role in influencing the particular 
course taken by a cell. For example, it has been suggested that intermediate levels of 
ROS result in growth arrest whereas severe oxidative stress causes cell death via either 
apoptotic or necrotic mechanisms (Martindale and Holbrook 2002). Here we 
demonstrated that the increase in hepatic iron concentration together with ROS 
accumulation was associated with increased cell death. These results are consistent 
with previous findings that suggested that iron overload induced apoptotic cell death in 
isolated rat hepatocytes which is thought to be mediated by reactive oxygen species 
(Allameh et al. 2008). The increase in cell death as determined by TUNEL was also 
associated with an increase in the ratio of Bax/Bcl-2 and Bad expression as well as 
caspase-3 cleavage, suggesting the involvement of apoptosis. Although similar findings 
have been demonstrated in vitro (Yajun, Hongshan et al. 2005), this is the first report 
that describes the effect of iron overload on the apoptotic cascade in intact liver.  As 
expected, deferasirox treatment was associated with lower cell death signal, Bax/Bcl-2 
ratio, Bad expression, and caspase-3 cleavage. These results suggest that apoptosis 
may be involved in iron overload induced hepatic toxicity and most importantly, that 
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deferasirox may confer protection against these effects. Nonetheless, given the 
important role of iron overload in cardiovascular and hepatic disorders, further studies 
are required to fully investigate the diversity and multiplicity of interactions between the 
signaling cascades involved in their pathogenesis. 
 
Effect of iron overload and deferasirox treatment on cardiac structure and 
function 
Iron overload is toxic to the heart, and in the syndromes of chronic iron overload 
the majority of deaths are due to cardiac failure and sudden death, with the latter 
probably due to arrhythmia. In animal studies, a dose relationship between iron load 
and the development of cardiac impairment is seen (Carthew, Dorman et al. 1993; 
Bartfay, Dawood et al. 1999; Yang, Dong et al. 2002). This wealth of evidence supports 
the hypothesis that cardiac complications in iron overload have a direct relationship with 
the amount of iron in the heart. Therefore, effective removal of cardiac iron is likely to 
reduce the incidence of cardiac complications associated with iron overload. In the 
present investigation, cardiac iron levels in the iron overloaded animals were 3.3 fold 
that of the control animals and were associated with structural and functional 
abnormalities including increased cardiac mass, ventricular remodeling, arrhythmia, 
valvular regurgitation, systolic dysfunction, and reduced survival. Chronic deferasirox 
administration reduced cardiac iron by 31.6% and this was associated with preserved 
cardiac structure and function along with improved survival. These results are in 
agreement with previous reports suggesting beneficial effects of chelation therapy with 
deferoxamine (Obejero-Paz, Yang et al. 2003; Yang, Brittenham et al. 2003) or 
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deferasirox (Kiguchi, Ito et al. 2009; Trad, Hamdan et al. 2009) in preventing/ reversing 
iron induced cardiac alterations.  
Although cardiac iron deposition, ROS accumulation, and biochemical changes 
were evident within a few weeks after iron loading, no significant changes in cardiac 
structure or function were observed until 6 and 9 months of follow up.  These 
observations resemble the time course of the disorder as described in humans. It has 
been reported that cardiac iron toxicity begins to occur after a total of 10 blood 
transfusions or approximately 5 g of iron; however, patients may remain asymptomatic 
for years. The symptoms of cardiac iron overload normally occur long after the probable 
initiation of cardiac iron accumulation with the mean survival falling to a few months 
once these complications have arisen (Wood, Enriquez et al. 2005). Intensive iron 
chelation therapy may help restore cardiac rhythm and function, which could increase 
survival. 
It is important to note here that iron deposition is not necessarily the sole cause 
of cardiac disease in iron overload conditions. It is well accepted that chronic anemia 
itself plays a role in the development of cardiovascular abnormalities regardless of 
cardiac iron status (Hahalis, Alexopoulos et al. 2005). For example, thalassemia is 
oftentimes associated with elevated cardiac output and stroke volume with the 
possibility of systolic dysfunction or severe pulmonary hypertension in advanced stages 
of the disease (Bosi, Crepaz et al. 2003). In the present investigation, the effect of the 
underlying condition on cardiac health was not examined and cannot be addressed from 
the present study design. The development of animal models that better resemble iron 
overload in these conditions will no doubt be useful in furthering our understanding of 
cardiac pathology in these diseases.  
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In conclusion, the work presented here strongly suggests a protective role of 
deferasirox against iron induced complications. Evidence from the clinical setting is 
needed to confirm these interesting findings and will no doubt be useful in developing 
better therapeutic regimens to control iron overload. 
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CONCLUSIONS 
 
1. Deferasirox treatment was found to remove iron from target tissues including 
heart, liver, and pancreas. Deferasirox treatment to a similar extent did not 
reduce iron accumulated in the kidney or aorta to a significant level.  
 
2. Iron overload was found to increase the relative expression of ferritin in both 
cardiac and hepatic tissue. Deferasirox treatment reduced iron-related 
increase in ferritin expression from both tissues. 
 
3. Deferasirox treatment was found to attenuate oxidative stress indices 
observed with iron overload from both cardiac and hepatic tissue. This 
includes the ability to reduce cumulative protein oxidation, superoxide 
overproduction, and MAPK phosphorylation. 
 
4. Deferasirox treatment was found to reduce iron overload-related cell death as 
well as the relative expression of members of the apoptotic cascade including 
Bax/Bcl-2, Bad, and caspase-3. 
 
5. Long term deferasirox treatment was found to further reduce accumulated 
tissue iron from heart, liver, and aorta. 
 
6. Iron overload was found to profoundly impact cardiac structure and function. 
Iron overload was associated with increase heart/body wt, left ventricular 
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interior and posterior dimensions, left ventricular septal thickness, frequency 
of arrhythmia and valvular regurgitation whereas ejection fraction and 
fractional shortening were decreased. Long term deferasirox treatment was 
found to preserve both cardiac structure and function. 
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FUTURE DIRECTIONS 
 
The present study focused on examining the efficacy of deferasirox treatment in 
preventing cardiac complications associated with iron overload. Future investigations 
should focus on examining whether deferasirox treatment is protective against other 
complications associated with iron overload including, among others, hepatic fibrosis, 
hepatocellular carcinoma, and diabetes mellitus.  
A critical target of future investigation would also be the assessment of the 
efficacy of combination therapy with other chelating agents or antioxidants. Previous 
research by Hershko and collegues (2001) have illustrated that the administration of 
DFO in combination with deferiprone provides a “shuttling effect” where the smaller and 
hydrophilic chelator deferiprone mobilized intracellular iron stores, subsequently 
transferring it to intra-  or extracellular DFO. Such a strategy was found to enhance iron 
excretion and reduce the side effects associated with monotherapy. Whether a 
combination therapy of DFO with deferasirox can induce a similar effect is worth 
investigating. 
Given the fact that oxidative stress is the major contributor to iron-induced 
toxicity, it is logical to propose that antioxidants might provide a protective effect. 
Recently, Duessel and collegues (Otto-Duessel, Aguilar et al. 2007) have demonstrated 
that the administration of the antioxidant taurine improved cardiac indices of oxidative 
stress in the iron overloaded gerbil. However, the effect of a combination therapy of 
antioxidants with iron chelation therapy is not known. Based on our understanding of the 
mechanisms involved in iron-induced toxicity and on previous research suggesting that 
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chelating agents improve the efficacy of antioxidants, we propose that the 
administration of deferasirox with antioxidants would provide a synergistic effect. 
Mitochondria and lysosomes are the major cellular targets of iron mediated 
damage. In vitro studies have suggested that deferasirox is able to cross the plasma 
membrane and access the cytoplasm. Whether deferasirox possesses accessibility to 
subcellular compartments is not known and is worth investigation. 
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